All posts by adm0n

Education & Training / 教育培训

Vocational education and skills training: 2026 access and compliance for foreign investors

  • The June 2026 “Action Plan for Stabilising and Optimising Foreign Investment” explicitly commits to steadily expanding the opening pilot for vocational-skills training institutions, vocational colleges and high-level science/agriculture/medicine/engineering universities.
    2026 年 6 月《利用外资固稳促优行动方案》明确承诺稳步扩大职业技能培训机构、职业院校、高水平理工农医类大学的对外开放试点。
  • Nanning’s Guangxi FTZ片区 is publicly consulting (from 3 July 2026) on rules permitting wholly foreign-owned for-profit vocational-skills training institutions (non-schooling type).
    广西自贸试验区南宁片区自 2026 年 7 月 3 日起公开征求意见，拟允许外商独资设立营利性（非学制类）职业技能培训机构。
  • Vocational training is governed by the Private Education Promotion Law, its implementation regulations, and the Sino–Foreign Cooperation in Running Schools Regulation; foreign wholly-owned schooling-type institutions remain constrained.
    职业培训受《民办教育促进法》及其实施条例、《中外合作办学条例》规制；外商独资的学制类教育机构仍受限制。
  • Sino–foreign cooperative vocational training sets a minimum scale (simultaneous training of no fewer than 200 persons in Yunnan’s standard) and requires provincial-level approval.
    中外合作职业培训机构设有最低规模标准（云南标准：同时培训不少于 200 人），并需省级审批。
  • The national negative list for foreign investment has been cut to 29 items with manufacturing fully opened, but education remains a sector requiring careful mapping against the list and the schooling/non-schooling divide.
    全国外资准入负面清单已压减至 29 条、制造业全面放开，但教育仍需对照清单及学制/非学制分界审慎判断。
  • Foreign investors should separate “schooling” (subject to tighter rules) from “training” (more open), and anchor pilots in FTZs where local implementing rules exist.
    外资应区分受更严监管的”学制类”与更开放的”培训类”，并依托已有地方实施细则的自贸片区落地试点。
  • Compliance pivots on licensing, the national training-fee supervision platform, and non-profit/for-profit classification where schooling is involved.
    合规关键在于办学许可、全国培训收费监管平台，以及涉及学制类时的非营利/营利分类。

Vocational education and skills training: 2026 access and compliance for foreign investors | 2026 外商投资职业教育与职业技能培训：准入与合规

Overview

Vocational education and skills training is one of the few education sub-sectors where China is actively widening the door to foreign capital in 2026. The signal is unambiguous: the *Action Plan for Stabilising and Optimising Foreign Investment*, issued on 22 June 2026 by the Ministry of Commerce (MOFCOM), the National Development and Reform Commission (NDRC) and the Ministry of Finance, lists “steadily expanding the opening pilot for vocational-skills training institutions, vocational colleges, and high-level science/agriculture/medicine/engineering universities” among its market-access measures. On the ground, free-trade zones are already moving: Nanning’s Guangxi FTZ片区 published, on 3 July 2026, a draft implementing rule for wholly foreign-owned for-profit vocational-skills training institutions (non-schooling type).

This article explains the legal scaffold, the 2026 openings, the FTZ pilots, and the compliance checklist for a foreign investor.

The legal scaffold

Three statutes frame the sector. The *Private Education Promotion Law* and its implementation regulations govern all non-government education, distinguishing for-profit from non-profit and schooling from training. The *Sino–Foreign Cooperation in Running Schools Regulation* specifically governs cooperative schools and training institutions with a foreign party. The *Vocational Education Law* sets the policy direction toward industry–education integration and enterprise participation.

Crucially, the line that matters most for foreign capital is schooling vs. non-schooling (培训). A “vocational college” (职业院校) or “schooling-type” institution confers qualifications through a formal education pathway and is treated as education proper, subject to tighter foreign-investment constraints. A “vocational-skills training institution (non-schooling type)” delivers skills training without conferring a formal academic qualification and is the segment now being opened to wholly foreign-owned investment in pilot zones.

The foreign-investment negative list is the other reference point. The national list has been cut to 29 items with manufacturing fully opened; education is not among the broadly liberalised items, so the opening for vocational training proceeds through *pilot* mechanisms and FTZ implementing rules rather than a blanket list removal.

The 2026 opening signals

The June 2026 Action Plan is the clearest statement. Its education opening measures are:

  • steadily expand the opening pilot for vocational-skills training institutions;
  • steadily expand the opening pilot for vocational colleges;
  • steadily expand the opening pilot for high-level science/agriculture/medicine/engineering universities.

The Plan also broadens the wholly foreign-owned hospital pilot and supports foreign-invested R&D centres with training bases — relevant because enterprise training and R&D talent development are adjacent opportunities. The policy framing is “shaping the new advantages of attracting foreign capital during the 15th Five-Year Plan” through services liberalisation.

FTZ pilots on the ground: Nanning and beyond

The most concrete 2026 move is Nanning’s Guangxi FTZ片区 draft (public comment 3 July – 2 August 2026) for * Measures for Wholly Foreign-Owned For-Profit Vocational-Skills Training Institutions (Non-Schooling Type)*. The draft is grounded in the *Foreign Investment Law*, the *Private Education Promotion Law* and its implementation regulations, the *Sino–Foreign Cooperation in Running Schools Regulation*, and the Guangxi FTZ regulations. It applies to foreign-owned for-profit non-schooling vocational training institutions established within the片区, signalling that the wholly foreign-owned training model is moving from concept to rule text.

Other localities show the cooperative (rather than wholly owned) route is already live. Yunnan’s 2026 adjustment of its *Vocational School Operating Licence Implementation Specification* (announced 20 March 2026) explicitly lists the sub-item “licensing for Sino–foreign, Guangdong/Hong Kong/Macao, and cross-strait cooperative vocational-skills training institutions”, with provincial-level approval and a minimum scale of simultaneously training no fewer than 200 persons. This confirms that cooperative vocational training is an established, approvable pathway even outside FTZs.

Compliance checklist

A foreign investor entering vocational training should plan around six pillars:

  1. Form choice: decide schooling vs. non-schooling. Non-schooling for-profit training is the pilot-opening segment; schooling-type or degree-granting activity remains constrained and generally requires cooperative (not wholly foreign-owned) structures.
  2. Licensing: obtain the private non-school education/training operating licence from the competent education or human-resources/social-security authority, then complete business registration. Operating without a licence is prohibited.
  3. Negative-list and FTZ alignment: anchor in a zone (e.g., Nanning Guangxi FTZ, or other FTZs issuing implementing rules) where the pilot explicitly permits the chosen model.
  4. Scale and faculty: meet setting standards — Yunnan’s cooperative standard requires capacity for at least 200 simultaneous trainees, qualified teachers and managers, and matching premises, equipment and curriculum.
  5. Fee supervision: vocational training fees fall under the national off-campus training supervision and service platform; pre-collected fees must enter a dedicated account, with caps (non-schooling off-campus training generally capped at RMB 5,000 per collection and no more than 3 months or 60 class-hours).
  6. Non-profit/for-profit split (if schooling): where the activity counts as schooling, the promoter cannot extract schooling gains if non-profit; for-profit requires the statutory classification and tax treatment.

Practical steps

  • Screen your offering: pure skills-upgrading for adults/employees fits the non-schooling training pilot; anything conferring a formal qualification trends toward schooling and cooperation.
  • Target an FTZ with a published or draft implementing rule (Nanning’s is open for comment in July–August 2026) and pre-engage the zone’s investment and education authorities.
  • Prepare the licence dossier early: articles, decision-body list, premises proof, teacher qualifications, and a feasible funding source.
  • Build the fee-management and platform-onboarding process before enrolment; retrospective compliance is costly.
  • If you intend cooperative delivery, identify a qualified domestic partner and budget for provincial approval timelines.

Sources

Related reading

  • see also: Online education and EdTech regulation for foreign investors (article 139)
  • see also: Non-academic after-school training and the foreign-investment boundary (article 140)
  • see also: Corporate training market for foreign and China-based employees (article 141)

2026 外商投资职业教育与职业技能培训：准入与合规

概述

职业教育与职业技能培训是 2026 年中国为数不多主动向外資敞开大门的教育细分领域。信号明确：2026 年 6 月 22 日商务部、国家发展改革委、财政部印发的《利用外资固稳促优行动方案》，将”稳步扩大职业技能培训机构、职业院校、高水平理工农医类大学对外开放试点”列入市场准入举措。落地层面，自贸区已在行动：广西自贸试验区南宁片区于 2026 年 7 月 3 日发布外商独资营利性（非学制类）职业技能培训机构的实施办法征求意见稿。

本文说明法律框架、2026 年开放举措、自贸区试点，以及外资的合规清单。

法律框架

三部法律构成该领域的骨架。《民办教育促进法》及其实施条例规制所有民办教育，区分营利与非营利、学制与培训；《中外合作办学条例》专门规制含外方的合作学校与培训机构；《职业教育法》确立产教融合、企业参与的政策方向。

对外资而言最关键的界线是学制类与非学制类（培训）。职业院校或学制类机构通过正规教育路径授予学历，被视为教育本体，受更严的外资约束；非学制类职业技能培训机构不授予正规学历，正是当前在试点区向外商独资开放的部分。

外资负面清单是另一参照。全国清单已压减至 29 条、制造业全面放开；教育不在普遍放开之列，因此职业培训的开放通过试点机制与自贸区实施细则推进，而非清单整体移除。

2026 年开放信号

2026 年 6 月的行动方案是最明确的表述，其教育开放举措包括：

  • 稳步扩大职业技能培训机构对外开放试点；
  • 稳步扩大职业院校对外开放试点；
  • 稳步扩大高水平理工农医类大学对外开放试点。

方案还扩大外商独资医院试点，并支持外资企业研发中心配套实训基地——这与企业培训、研发人才培养等相邻机会相关。政策基调是”以服务业开放塑造十五五期间吸引外资新优势”。

自贸区试点：南宁及更广实践

最具体的 2026 动作，是南宁广西自贸片区 7 月 3 日至 8 月 2 日公开征求意见的《外商独资设立经营性职业技能培训机构（非学制类）实施办法》。草案依据《外商投资法》《民办教育促进法》及其实施条例、《中外合作办学条例》及广西自贸区条例，适用于片区内设立的外商独资非营利学制类之外的经营性非学制类职业培训机构，显示外商独资培训模式正从概念走向规则文本。

其他地区表明合作（而非独资）路径已经可行。云南 2026 年 3 月 20 日动态调整的《职业培训学校办学许可实施规范》，明确列出”中外、内地与港澳、大陆与台湾合作办学的职业技能培训机构办学许可”子项，由省级审批，最低规模要求同时培训不少于 200 人。这印证了合作制职业培训即便在自贸区外也是既成、可批的路径。

合规清单

进入职业培训的外资应围绕六大支柱规划：

  1. 形式选择： 区分学制与非学制。非学制营利性培训是试点开放部分；学制类或授予学历的活动仍受约束，通常需合作（而非外商独资）结构。
  2. 办学许可： 向教育或人社主管部门取得民办教育培训办学许可，再完成商事登记；无证办学被禁止。
  3. 清单与自贸区对齐： 锚定已明确允许该模式的片区（如南宁广西自贸区或其他出台实施细则的自贸区）。
  4. 规模与师资： 满足设置标准——云南合作标准要求同时培训不少于 200 人、具备合格师资与管理人、匹配场所设备与课程。
  5. 收费监管： 职业培训收费纳入全国校外教育培训监管与服务综合平台；预收费须进专用账户并设上限（非学科类校外培训一般单次不超 5000 元、不超 3 个月或 60 课时）。
  6. 非营利/营利划分（涉学制时）： 若活动属学制类，非营利性办学者不得取得办学收益；营利性须履行法定分类与税务处理。

实操步骤

  • 筛选业务：面向成人/员工的纯技能提升契合非学制培训试点；凡授予正规学历的趋向学制与合作办学。
  • 选择已发布或征求意见稿的自贸区（南宁稿 2026 年 7–8 月征求意见），提前对接片区投促与教育主管部门。
  • 尽早准备许可案卷：章程、决策机构名单、场所证明、师资资格、稳定经费来源。
  • 在招生前搭建收费管理与平台接入流程；事后合规成本高昂。
  • 若拟合作办学，遴选合格国内合作方，并为省级审批周期预留预算。

来源

相关阅读

  • 见：外资在线教育/EdTech 监管现状（第 139 篇）
  • 见：非学科类校外培训外资参与边界（第 140 篇）
  • 见：面向外资企业的员工培训服务市场（第 141 篇）
Greater Bay Area / 大湾区

Zhuhai–Macao Ports Upgrade the “Joint Inspection, One-Stop Release” Model: What It Means for Greater Bay Area Travel (August 2026)

  • From 18 August 2026, three cooperation-inspection ports — Hong Kong–Zhuhai–Macao Bridge, Hengqin and Qingmao — introduced three measures optimising the “joint inspection, one-stop release” model.
    自 2026 年 8 月 18 日起，港珠澳大桥、横琴、青茂三个合作查验口岸实施优化”合作查验、一次放行”查验模式的三项便利措施。
  • Macao residents and Hong Kong permanent residents may now use their Home Return Permit (including the non-Chinese-national version) in both directions at the cooperation fast lanes, realising “one-card clearance”.
    澳门居民与香港永久性居民经合作快捷通道可双向交验回乡证（含非中国籍），实现”一证通关”。
  • Chinese citizens holding a one-year multi-entry exit-entry permit can use the cooperation fast lanes at the Hong Kong–Zhuhai–Macao Bridge and Hengqin ports after completing e-channel filing.
    持一年多次有效出入境通行证的中国公民，在办妥快捷通关备案后，可经港珠澳大桥珠澳查验大厅、横琴口岸合作快捷通道通行。
  • Eligible foreigners and Taiwan residents may now drive through the “joint one-stop” lane at Hengqin port after filing, broadening the lane beyond Hong Kong and Macao residents.
    符合条件的外国人与台湾居民在办妥备案后，可以驾车经横琴口岸”联合一站式”车道通行，通行人群大幅拓宽。
  • Clearance time at the Hengqin “joint one-stop” lane has been cut from 8 minutes to under 90 seconds per vehicle, with the fastest at about 50 seconds.
    横琴口岸”联合一站式”车道单台车通关时间已从 8 分钟压缩至 90 秒以内，最快约 50 秒。
  • Traffic through the three ports reached 42 million person-trips in H1 2026, up 12.8% year on year, showing the corridor’s growing role for regional business travel.
    2026 年上半年经三个口岸出入境客流累计达 4200 万人次，同比增长 12.8%，显示该通道对区域商务往来的作用日益增强。

Zhuhai–Macao Ports Upgrade the “Joint Inspection, One-Stop Release” Model: What It Means for Greater Bay Area Travel (August 2026) | 珠海—澳门口岸升级”合作查验、一次放行”模式：对粤港澳大湾区往来意味着什么（2026 年 8 月）

Why this matters now

On 18 August 2026, with approval from the Exit-Entry Administration and after coordination between the Zhuhai General Station of Exit-Entry Frontier Inspection and the Macao Public Security Police Force, three cooperation-inspection ports — Hong Kong–Zhuhai–Macao Bridge, Hengqin and Qingmao — began implementing three facilitation measures under the “joint inspection, one-stop release” (合作查验、一次放行) model. The measures expand the categories of travellers who can use the cooperation fast lanes and the “joint one-stop” vehicle lane, and simplify the documents that Macao and Hong Kong residents must present. For multinational companies with Greater Bay Area (GBA) operations, the change reduces the administrative cost of cross-border commuting between Zhuhai, Macao, Hengqin and Hong Kong — an increasingly important factor for regional headquarters, R&D and supply-chain staff.

What the three measures change

The first measure makes document handling more flexible. Macao residents and Hong Kong permanent residents travelling through the cooperation fast lanes at the three ports, and through the Hengqin vehicle lane, may now present either their ID cards or their Home Return Permit (including the version for non-Chinese nationals) in both directions. Previously, travellers had to switch documents depending on travel direction. The change effectively delivers “one-card clearance” and removes a common source of confusion at the gates.

The second measure widens the eligible population for the cooperation fast lanes. Chinese citizens who hold a one-year multi-entry People’s Republic of China Exit-Entry Permit, and who have completed the e-channel filing with both the mainland and Macao border inspection authorities, may use the fast lanes at the Hong Kong–Zhuhai–Macao Bridge port inspection hall and the Hengqin port (restricted to the ports for which they have filed). This is the latest step in a process that has gradually converged eligibility across different fast-lane categories.

The third measure is the most significant for foreign nationals. After completing e-channel filing, eligible foreigners and Taiwan residents may now drive through the “joint one-stop” vehicle lane at Hengqin port. Eligible foreigners include: those holding a foreign passport plus a Foreigner’s Permanent Residence ID Card; and those holding a foreign e-passport plus either a residence permit valid for more than six months or a multi-entry Chinese visa valid for more than six months (and who also meet Macao’s conditions for repeated entry). The lane, which has cut per-vehicle clearance from eight minutes to under 90 seconds since launch, now serves a much broader cross-border driving population.

Practical implications for business

For regional employers and their expatriate and cross-border staff, the practical effects are measurable. First, Hong Kong–Macao commuting for GBA staff becomes faster and less document-sensitive, which helps with meetings, audits and shift-based operations across Zhuhai and Macao. Second, foreign nationals who qualify for the Hengqin vehicle lane gain a materially faster route between Macao and Hengqin — the base for the Guangdong-Macao In-Depth Cooperation Zone — which is relevant for the growing number of foreign-invested operations in the zone. Third, the volume growth at these ports (42 million person-trips in the first half of 2026, up 12.8% year on year) signals sustained demand that makes smooth, compliant clearance a business-relevant capability rather than an administrative detail.

Practical steps for companies and travellers

  1. Check eligibility for the vehicle lane. Foreign staff who hold a permanent residence card, or a qualifying residence permit or long-term multi-entry visa plus Macao re-entry rights, should complete the e-channel filing with both border authorities before relying on the lane.
  2. Standardise document packs for fast lanes. Ensure Macao/Hong Kong resident employees use the Home Return Permit consistently in both directions and understand the “one-card” option.
  3. Update internal travel guidance. Mobility teams in the GBA should refresh instructions for mainland staff who hold the one-year multi-entry permit and wish to use the cooperation fast lanes.
  4. Plan clearance time realistically. Even with sub-90-second lanes, peak-hour queues remain; schedule cross-border meetings with buffer time.
  5. Keep filings current. E-channel registrations are tied to specific ports and document validity; renew passports, permits and visas in time to avoid losing the convenience.
  6. Watch for further port-level expansion. The model has been replicated across ports since 2018 and may extend to more crossing points and traveller categories.

Compliance notes

These are operational facilitation measures, not changes to immigration status or border-control legal requirements. Travellers must still hold valid documents and comply with the purpose-of-stay rules of their entry categories. The “one-stop release” speeds inspection but does not relax entry conditions; business visitors who need to work in China for longer periods or take up employment must still use the work permit and residence permit routes. Vehicle drivers must also meet all mainland and Macao driving and insurance requirements. As with all exit-entry policy, the practical implementation can be adjusted, so companies should verify current port-level rules before major cross-border events.

珠海—澳门口岸升级”合作查验、一次放行”模式：对粤港澳大湾区往来意味着什么（2026 年 8 月）/ Zhuhai–Macao Ports Upgrade the “Joint Inspection, One-Stop Release” Model: What It Means for Greater Bay Area Travel (August 2026)

为什么当下重要

2026 年 8 月 18 日，经中华人民共和国出入境管理局批准，珠海出入境边防检查总站与澳门治安警察局协商，在港珠澳大桥、横琴、青茂三个合作查验口岸正式实施优化”合作查验、一次放行”查验模式的三项便利措施。三项措施扩大合作快捷通道与”联合一站式”车道的适用人群，并简化澳门、香港居民须出示的证件。对在粤港澳大湾区设有业务的跨国企业而言，这项调整降低了珠海、澳门、横琴与香港之间跨境通勤的行政成本——对区域总部、研发与供应链人员日益重要。

三项措施改变了什么

第一项措施使证件交验更灵活。澳门居民及香港永久性居民经三个口岸的合作快捷通道、以及横琴口岸车辆”联合一站式”通道通行时，出入境双向既可交验身份证，也可交验回乡证（含非中国籍版本）。此前旅客需按通行方向切换证件。此举实质上实现”一证通关”，消除了闸口常见的证件混淆问题。

第二项措施扩大合作快捷通道适用人群。持一年多次有效中华人民共和国出入境通行证的中国公民，在办妥内地与澳门边检机关快捷通关备案手续后，可经港珠澳大桥珠海公路口岸珠澳查验大厅、横琴口岸合作快捷通道通行（限已备案口岸）。这是各类快捷通道适用人员范围逐渐趋同的又一进展。

第三项措施对外籍人士意义最大。在办妥内地与澳门边检机关快捷通关备案手续后，符合条件的外国人和台湾居民可以驾车经横琴口岸”联合一站式”车道通行。符合条件的外国人包括：持外国护照及外国人永久居留身份证的外国人；持外国电子护照及 6 个月以上外国人居留许可或 6 个月以上多次有效中国签证的外国人（须同时符合外国人多次进入澳门的条件）。该车道自启用以来单台车通关时间已从 8 分钟压缩至 90 秒以内，如今服务更多跨境驾车人群。

对企业的实操影响

对区域雇主及其外派与跨境员工而言，实际效果可量化。其一，大湾区员工的港澳通勤更快、对证件更不敏感，有利于珠海与澳门间的会议、审计与倒班运营。其二，符合条件的外籍人士在横琴车辆通道上获得澳门与横琴之间更快的路径——横琴是粤澳深度合作区所在地，对区内日益增多的外资运营至关重要。其三，这些口岸的客流增长（2026 年上半年 4200 万人次，同比增 12.8%）表明需求持续旺盛，顺畅合规通关日益成为与业务相关的能力，而非行政细节。

公司与旅客的操作步骤

  1. 核验车辆通道资格。 持永久居留身份证、或符合要求的居留许可/长期多次签证且具备澳门再入境条件的外籍员工，应先在两地边检完成电子通道备案。
  2. 标准化快捷通道证件包。 确保港澳居民雇员双向一致使用回乡证，并理解”一证通行”选项。
  3. 更新内部出行指引。 大湾区的差旅团队应为持一年多次出入境通行证的大陆员工更新合作快捷通道使用说明。
  4. 留出通关缓冲。 即便车道低于 90 秒，高峰仍可能排队；跨境会议应预留时间。
  5. 保持备案有效。 电子通道备案绑定特定口岸与证件有效期；及时更新护照、通行证与签证以免失去便利。
  6. 关注口岸级扩容。 该模式自 2018 年起跨口岸复制推广，可能继续延伸至更多口岸与人群。

合规提示

这些是操作性便利措施，不是移民身份或边检法定要求的变化。旅客仍须持有效证件并遵守其入境类别的停留目的规则。”一次放行”加快查验，但不放宽入境条件；需要在华长期工作或就职的商务访客仍须走工作许可与居留许可路径。驾车人员还须满足内地与澳门的全部驾驶与保险要求。与所有出入境政策一样，实际执行细节可能调整，重大跨境活动前应核实现行口岸规则。

Sources

Greater Bay Area / 大湾区

Shenzhen’s 19 Port Measures and the Greater Bay Area Opportunity for Foreign Business

  • Shenzhen released 19 measures to optimise its port business environment in August 2026, timed to the APEC leaders’ meeting hosted in the city.
    深圳于2026年8月发布优化口岸营商环境19条举措，恰逢该市承办APEC领导人会议。
  • The package upgrades cross-border clearance: an APEC green lane, “one-check, one-release” at the new Huanggang port, and face/iris contactless passage at road ports.
    一揽子举措升级跨境通关：APEC绿色通道、新皇岗口岸”合作查验、一次放行”、公路口岸刷脸/虹膜无感通关。
  • Qianhai comprehensive bonded zone pilots a “front-line direct, smart-linked supervision” model that lets goods move to the zone for sorting before full customs clearance.
    前海综合保税区试点”一线直通、智联监管”模式，允许货物在完整清关前提离至综保区理货集拼。
  • Cross-border e-commerce gets “inspect-before-load” reform, a “sunshine 2.0” system and facilitated rebates for white-list firms.
    跨境电商获得”先查验后装运”改革、”阳光化2.0″体系，以及对白名单企业的便利化退税。
  • Inbound services improve: two new duty-free shops, depart-and-refund smart terminals, an “all-area payment demonstration zone” and an upgraded AI city travel card.
    入境服务提升：新增2家进境免税店、离境退税智能终端、”全域支付示范区”与升级版AI城市旅行卡。
  • Practical step: map your import/export and talent-mobility flows to the 19 measures; pilot Qianhai and APEC-lane options early.
    实操建议：将进出口与人才流动链路对照19条；尽早试点前海与APEC绿色通道选项。

Shenzhen’s 19 Port Measures and the Greater Bay Area Opportunity for Foreign Business | 深圳口岸19条与大湾区外资机遇

In August 2026 Shenzhen rolled out the *Several Measures for Optimising the Port Business Environment in 2026* — 19 concrete measures spanning clearance efficiency, infrastructure, inbound services and new trade forms. Released against the backdrop of the APEC leaders’ meeting hosted in the city, the package is the latest signal that the Greater Bay Area (GBA) is competing on cross-border convenience as much as on policy.

Clearance efficiency upgrades

The measures upgrade the port environment for the APEC meeting and beyond:

  • APEC green lane. A dedicated fast channel for APEC participants, with multilingual signage and translation/guidance materials.
  • Manufacturing-tailored clearance. Processes for raw-material import and finished-goods export are optimised for advanced manufacturing.
  • Qianhai “front-line direct, smart-linked supervision.” Eligible goods may be moved to the comprehensive bonded zone for sorting and consolidation before full clearance, under fully digital, visualised and intelligent supervision.
  • Border-inspection “zero-wait” arrival and “zero-delay” departure, plus maritime conveniences such as pre-arrival inspection and “leave-without-inspection” for departures.

Infrastructure and new trade forms

  • New Huanggang port opens with “co-operative inspection, one release” — a single crossing for both jurisdictions.
  • Luohu upgrade and Sham Chun Kok reconstruction proceed; the Shanwei Bay cold-chain inspection desk is operational.
  • Contactless passage via face recognition at road ports, with a face + iris smart lane piloted at Shenzhen Bay.
  • Cross-border low-altitude logistics. Shenzhen explores drone cross-border logistics and cross-border flight management, advancing Shenzhen–Hong Kong drone trial flights and eVTOL supervision research.
  • E-commerce reform. “Inspect-before-load” embeds customs checks into sorting/pick-and-pack, cutting handling loss; “Sunshine 2.0” builds a six-in-one (commerce, customs, exchange, tax, loan, insurance) oversight system, with classified management for white-list firms and facilitated rebates.

Inbound services and the foreign-visitor experience

The package directly improves the experience of foreign business travellers and residents:

  • Two new duty-free shops at ports and an “e-commerce pre-order, port pickup” model.
  • Departure-tax refund smart service islands and self-service terminals.
  • All-area payment demonstration zone: new or upgraded overseas-visitor payment service centres at key ports with foreign-card ATMs and currency exchange.
  • Upgraded “Shenzhen AI City Travel Card” integrating payment, transport and tourism.
  • Cruise and yacht liberalisation: expanded yacht free-trade waters, a “two-plate” management model for Hong Kong–Macao yachts, and self-service medical exams for licence conversion.

Why this matters for foreign investors

The GBA is where many foreign manufacturers, trading houses and brand operators concentrate their China footprint. The 19 measures cut two kinds of cost: time-at-the-border (faster clearance, smart supervision) and talent-and-travel friction (APEC lane, payment, tax refund). For firms moving goods through Qianhai or Shenzhen ports, the “front-line direct” model can compress working-capital cycles; for firms rotating expatriate and regional staff, the travel-card and payment upgrades reduce everyday friction.

Practical steps

  1. Map flows to measures. List your import/export lanes and staff-travel patterns; tag each against the 19 measures.
  2. Pilot Qianhai. If you import/export via Shenzhen, trial the “front-line direct” bonded model for consolidation.
  3. Use the APEC lane. Equip eligible staff with APEC cards to use the green lane during the meeting period and beyond.
  4. Join e-commerce white lists. If you sell cross-border, pursue the “Sunshine 2.0” white-list status for rebate facilitation.
  5. Brief travellers. Issue the AI city travel card and pre-register payment centres for visiting executives.

深圳口岸19条与大湾区外资机遇

2026年8月，深圳出台《深圳市2026年优化口岸营商环境若干措施》——19条具体举措，覆盖通关效率、基础设施、入境服务与新业态。举措发布正值该市承办APEC领导人会议之际，是粤港澳大湾区以跨境便利参与竞争的最新信号。

通关效率升级

举措为APEC会议及更长期升级口岸环境：

  • APEC绿色通道。 为APEC参会人员设快速通道，配多语种标识与翻译指引资料。
  • 制造业导向通关。 优化先进制造业原材料进口与成品出口流程。
  • 前海”一线直通、智联监管”。 符合条件的货物可在完整清关前提离至综合保税区理货集拼，全程数字化、可视化、智能化监管。
  • 边检”零等待”到港、”零延时”验放，以及抵港预检、离港”临开不查”等海事便利。

基础设施与新业态

  • 新皇岗口岸以”合作查验、一次放行”模式启用，一次过境覆盖两地。
  • 罗湖口岸改造与沙头角口岸重建推进；深圳湾口岸入境冷链查验台已启用。
  • 公路口岸刷脸无感通关，深圳湾试点人脸+虹膜智能通道。
  • 跨境低空物流。 深圳探索无人机物流通关与跨境飞行管理，推进深港跨境无人机试飞与eVTOL监管研究。
  • 电商改革。 “先查验后装运”将海关查验嵌入理货分拣，降低货损；”阳光化2.0″构建”商、关、汇、税、贷、保”六位一体监管，对白名单企业分类管理并便利化退税。

入境服务与外籍人士体验

举措直接改善外国商务旅客与居民的体验：

  • 口岸新增2家进境免税店，探索”电商预购、口岸提货”。
  • 离境退税智能服务岛与自助终端。
  • “全域支付示范区”：重点口岸新建或改造境外旅客支付服务中心，配备外卡取现与外币兑换。
  • 升级“深圳AI城市旅行卡”，整合支付、交通与文旅。
  • 邮轮游艇便利：扩大游艇自由行水域，建立港澳游艇”两套牌”管理，推行驾驶证换证体检自助办理。

对外资的意义

大湾区是众多外资制造、贸易与品牌运营商在华布局的集中地。19条削减两类成本：边境时间（更快通关、智能监管）与人才与出行摩擦（APEC通道、支付、退税）。经前海或深圳口岸进出货物的企业，”一线直通”模式可压缩营运资金周期；高频轮换外籍与区域员工的企业，旅行卡与支付升级降低日常摩擦。

实操步骤

  1. 对照措施制图。 列出进出口通道与员工出行模式，逐条对应19条。
  2. 试点前海。 经深圳进出口的企业，试用”一线直通”保税集拼模式。
  3. 用APEC通道。 为符合条件的员工办理APEC卡，在会议期及之后使用绿色通道。
  4. 加入电商白名单。 跨境销售企业争取”阳光化2.0″白名单身份以获退税便利。
  5. 提示出行人员。 为来访高管发放AI城市旅行卡并预登记支付服务中心。

Practitioner Quick Reference

  • 19 measures, August 2026: Shenzhen’s port-business-environment package, APEC-timed.
    19条（2026年8月）：深圳口岸营商环境一揽子举措，与APEC同期。
  • Qianhai “front-line direct”: move goods to the bonded zone for sorting before full clearance.
    前海”一线直通”：完整清关前将货物提离至综保区理货。
  • APEC green lane + AI travel card: faster crossing and easier in-city payment for foreign staff.
    APEC绿色通道加AI旅行卡：外籍员工更快过境、市内支付更便捷。
  • E-commerce “inspect-before-load” + Sunshine 2.0: white-list firms get facilitated rebates.
    电商”先查验后装运”加阳光化2.0：白名单企业获便利化退税。

Common Pitfalls

  • Treating it as Shenzhen-only: Qianhai and GBA linkage mean benefits can extend to Hong Kong–Macao flows.
    误以为仅限深圳：前海与大湾区联动使利好可延伸至港澳流向。
  • Missing the bonded-model window: “front-line direct” requires eligibility and advance setup, not a walk-up.
    “一线直通”需资质与前置准备，非随到随用。
  • Underusing payment/tax-refund upgrades: foreign travellers often don’t claim available rebates and exchange convenience.
    未充分利用支付与退税升级：外国旅客常未申领可用退税与兑换便利。

Sources

Greater Bay Area / 大湾区

Greater Bay Area: opportunities for SMEs

  • The GBA is built on “one country, two systems, three customs territories, three legal systems” — Hong Kong and Macao are separate customs territories from the nine Guangdong mainland cities.
    大湾区以”一个国家、两种制度、三个关税区、三种法律体系”为基础——香港、澳门与广东九市分属不同的关税区与法律体系。
  • The IIT subsidy for overseas high-end and urgently-needed talent effectively caps the top individual burden at about 15% in the nine Guangdong cities.
    对境外高端和紧缺人才的个人所得补贴，在广东九市将个人实际税负上限控制在约 15%。
  • The GBA IIT preferential policy runs through 31 December 2027 under Cai Shui [2019] No. 31 and its extension Cai Shui [2023] No. 34.
    大湾区个税优惠政策依据财税〔2019〕31 号及其延续文件财税〔2023〕34 号，执行至 2027 年 12 月 31 日。
  • The subsidy is capped per taxpayer per year (Guangdong sets a local maximum of RMB 5 million per taxpayer per year).
    补贴设单人年度上限（广东省地方细则规定每名纳税人每年最高 500 万元）。
  • Market access follows the 2024 national foreign-investment negative list, which cut nationwide restrictions to 29 items with manufacturing fully opened.
    市场准入遵循 2024 年全国外资准入负面清单，限制措施压减至 29 条，制造业已全面放开。
  • The pilot cooperation zones — Qianhai (modern services), Nansha (trade/shipping), Hengqin (Macao), HK–SZ Loop (R&D) — offer additional sector-specific opening that applies only inside the zone.
    前海（现代服务业）、南沙（贸易航运）、横琴（澳门）、河套（研发）等试点合作区，在区内提供额外的行业开放，且仅在区内适用。
  • The cross-boundary lock model and streamlined port clearance shorten transit times and lower logistics cost for cross-border goods.
    “跨境一锁”模式与简化口岸清关，缩短跨境货运时长并降低物流成本。
  • Use Hong Kong as a regional holding, financing and IP base while operating a Mainland WFOE for production and sales.
    以香港作为区域控股、融资与知识产权基地，同时以内地 WFOE 承载生产与销售。

Greater Bay Area: opportunities for SMEs | 粤港澳大湾区：中小企业的机遇

Overview

The Guangdong–Hong Kong–Macao Greater Bay Area (GBA) is a city-cluster strategy that bundles Hong Kong, Macao and nine municipalities in Guangdong province — Guangzhou, Shenzhen, Zhuhai, Foshan, Huizhou, Dongguan, Zhongshan, Jiangmen and Zhaoqing — into a single integrated economic space. As set out in the *Outline Development Plan for the Guangdong–Hong Kong–Macao Greater Bay Area* (issued by the CPC Central Committee and the State Council in February 2019), the GBA covers about 56,000 square kilometres and, as of 2017, had a population of roughly 70 million and an economic aggregate of around RMB 10 trillion (about USD 1.6 trillion in 2018). For a foreign small or medium-sized enterprise (SME), the GBA is not one market but a layered platform: a global financial and services hub in Hong Kong, a tourism-and-diversification base in Macao, and a vast advanced-manufacturing and innovation hinterland across the nine mainland cities.

This article explains, in practical terms, what the integration means for a foreign SME, how goods and talent now move across the “three customs territories and three legal systems”, and which incentives and market-access channels are realistically available to foreign-invested smaller businesses.

The integration framework and why it matters to SMEs

The GBA’s defining feature is what Chinese policy documents call “one country, two systems, three customs territories, three legal systems”. Hong Kong and Macao are separate customs territories with their own currencies, tax systems and common-law/civil-law traditions; the nine Guangdong cities sit inside the Mainland customs and legal system. Integration therefore does not mean merging the three systems — it means building “soft connectivity” (规则衔接、机制对接) so that factors of production flow more efficiently while each side keeps its own regime.

For an SME this has two consequences. First, the GBA gives a foreign firm a low-friction way to use Hong Kong as a regional holding, financing and IP base while operating production and sales on the Mainland side. Second, the integration agenda actively lowers friction for smaller players: simplified customs models, mutual recognition of professional qualifications, and a growing set of fiscal subsidies aimed at attracting overseas (including foreign, HK/Macao and Taiwanese) high-end and urgently-needed talent. The strategic positioning named in the Plan is fivefold — a world-class city cluster, an international science-and-technology innovation centre, a support pillar for the Belt and Road, a demonstration zone for in-depth mainland–HK/Macao cooperation, and a liveable, workable and tourist-friendly quality-living circle.

Cross-border flow of goods and talent

Goods: The Mainland and Hong Kong have rolled out the “cross-boundary lock” (跨境一锁) model across the GBA, and the Mainland–Macao version has started. Port clearance has been streamlined, with models such as “cooperative inspection, one-time release” (合作查验、一次放行) at the HZMB Zhuhai–Macao port and “one-stop two-system inspection” (一地两检) at Hong Kong’s West Kowloon station. For SMEs this translates into shorter transit times and lower logistics cost on cross-border shipments.

Talent: Cross-boundary mobility is the most practical benefit for a knowledge-intensive SME. The Mainland side has recognised or made facilitation arrangements for professional qualifications from HK/Macao in eight key fields — construction, healthcare, education, law, accounting, tourism and others. Hong Kong and Macao residents working in the nine cities are, subject to local rules, now able to buy property, enroll their children in local schools, and participate in the local social-insurance system. For foreign (non-Chinese) staff, the GBA’s talent policies are layered on top of national visa and work-permit rules, and several cities operate “green channel” pathways for research and innovation leaders.

Capital: On the financial side, a unified RMB/foreign-currency cross-border cash-pool business has been launched, the cross-boundary Wealth Management Connect (跨境理财通) pilot is advancing, and cross-boundary motor-vehicle insurance (“one policy, three places”) is being trialled. These are most relevant to SMEs with cross-border treasury needs, though they remain subject to mainland capital-account and conduct rules.

Incentives and market access for foreign SMEs

The single most relevant fiscal tool for a foreign SME with people in the GBA is the individual income tax (IIT) subsidy for overseas high-end and urgently-needed talent. Under the *Notice on Preferential Individual Income Tax Policies for the Guangdong–Hong Kong–Macao Greater Bay Area* (Cai Shui [2019] No. 31) and its extension *Cai Shui [2023] No. 34, the nine Guangdong cities grant a fiscal subsidy equal to the difference between the IIT actually paid and the Hong Kong tax level, and that subsidy is exempt from IIT. In practice the effect is that the effective top burden is capped at roughly 15% for qualifying individuals. The policy currently runs through 31 December 2027. Eligibility is determined by Guangdong and the respective city governments, and the subsidy is capped per taxpayer per year (for example, Guangdong sets a maximum of RMB 5 million per taxpayer per year under local implementing rules).

For the enterprise itself, market access follows the national negative list for foreign investment (the 2024 version cut nationwide restrictions to 29 items, with manufacturing fully opened), and inside the GBA’s pilot cooperation zones — Qianhai (Shenzhen–HK modern services), Nansha (Guangzhou), Hengqin (Guangdong–Macao) and the HK–SZ Loop (Heung Yuen Wai / Futian) — additional openness and facilitation apply. Foreign SMEs in advanced manufacturing, cross-border services, technology and healthcare should check both the national list and the local pilot catalogue, because the zone’s more liberal rule applies within the zone.

Practical landing paths

Most foreign SMEs enter the GBA through one of two doors. Door one is Hong Kong: incorporate a Hong Kong company to hold IP and regional contracts, then set up a Wholly Foreign-Owned Enterprise (WFOE) or representative structure in a GBA mainland city for production and sales. Door two is a direct mainland WFOE in one of the cooperation zones, which can offer sector-specific opening and administrative convenience. The Qianhai, Nansha and Hengqin plans each “misalign” their positioning — Qianhai leans modern services, Nansha leans comprehensive cooperation and shipping, Hengqin leans Macao diversification — so the choice of zone should follow the business model rather than a generic “GBA” label. Guangdong has also built a network of youth innovation-and-entrepreneurship bases (around a dozen), through which HK/Macao and overseas young founders can access incubation, subsidies and local procurement links.

What to do next

  • Confirm whether your target sector is off the national foreign-investment negative list, then re-check the specific Qianhai / Nansha / Hengqin pilot catalogue for any extra opening.
  • If you will employ foreign or HK/Macao senior staff in the nine cities, model the IIT subsidy (Cai Shui [2019] No. 31 / [2023] No. 34) early — it can materially lower your fully-loaded employment cost through 2027.
  • Choose a landing zone by fit: Qianhai for services, Nansha for trade/shipping, Hengqin for Macao-linked activity, the Loop for R&D.
  • Use Hong Kong as your regional treasury, IP and contract hub where group structure allows, while operating a Mainland WFOE for substance.
  • Plan customs and logistics around the cross-boundary lock and streamlined port models if you move goods between HK/Macao and the mainland.
  • Engage a local adviser on professional-qualification recognition before relocating key technical or professional staff.

Sources

Related reading

  • see also: Lingang & free trade zones playbook
  • see also: Hainan talent & tax measures expanded
  • see also: Tax treaty benefits for foreign investors

粤港澳大湾区：中小企业的机遇

概述

粤港澳大湾区（GBA）是一项城市群战略，将香港、澳门以及广东省九个城市——广州、深圳、珠海、佛山、惠州、东莞、中山、江门、肇庆——整合为统一的经济空间。根据《粤港澳大湾区发展规划纲要》（中共中央、国务院于 2019 年 2 月印发），大湾区总面积约 5.6 万平方公里，2017 年末总人口约 7000 万，经济总量约 10 万亿元人民币（2018 年约合 1.6 万亿美元）。对外国中小企业（SME）而言，大湾区不是单一市场，而是一个分层平台：香港是国际金融与服务枢纽，澳门是旅游与多元化基地，广东九市则是庞大的先进制造业与创新腹地。

本文以实务视角说明，区域一体化对外国中小企业意味着什么、货物与人才如何在”三个关税区、三种法律体系”之间流动，以及外国投资的中小企业可以实际运用的激励措施与市场准入渠道。

一体化框架及其对中小企业的意义

大湾区最鲜明的特征是政策文件所称的”一个国家、两种制度、三个关税区、三种法律体系”。香港、澳门是独立的关税区，拥有各自的货币、税制与普通法/大陆法传统；广东九市则处于内地关境与法律体系之内。因此，一体化并非合并三套制度，而是建设”规则衔接、机制对接”，在各自保留自身制度的前提下，让生产要素更高效流动。

对中小企业而言，这带来两方面后果。其一，大湾区为外国企业用香港作为区域控股、融资与知识产权基地、同时在内地一侧开展生产与销售，提供了低摩擦路径。其二，一体化议程主动为中小参与者降低摩擦：简化海关模式、互认职业资格，以及一系列旨在吸引境外（含外国、港澳及台湾）高端与紧缺人才的财政补贴。纲要提出的战略定位有五：充满活力的世界级城市群、具有全球影响力的国际科技创新中心、”一带一路”建设的重要支撑、内地与港澳深度合作示范区、宜居宜业宜游的优质生活圈。

货物与人才的跨境流动

货物：内地与香港已在大湾区全面实施”跨境一锁”模式，与澳门的”跨境一锁”业务也已启动；口岸清关进一步简化，港珠澳大桥珠澳口岸实行”合作查验、一次放行”，香港西九龙站实行”一地两检”。对中小企业而言，这意味着跨境货运时间更短、物流成本更低。

人才：跨境人员流动是知识密集型中小企业最实际的红利。内地一侧已在建筑工程、医疗、教育、法律、会计、旅游等八个重点领域实现对港澳职业资格的认可或便利安排。在九市工作生活的港澳居民，在符合条件时可购房、子女就地入学并参加内地社会保险。对于外国（非华裔）员工，大湾区的才政策叠加在国家的签证与工作许可规则之上，多个城市为科研创新领军人才开设”绿色通道”。

资金：金融方面，本外币合一的跨境资金池业务已落地，跨境理财通试点稳步推进，跨境车险”三地保单、一地购买”开始试点。这些对具备跨境财资需求的中小企业最有价值，但仍受内地资本项目与行为监管规则约束。

面向外国中小企业的激励与市场准入

对外国中小企业在大湾区配置人员而言，最相关的财政工具是境外高端紧缺人才的个人所得税补贴。依据《关于粤港澳大湾区个人所得税优惠政策的通知》（财税〔2019〕31 号）及其延续文件《关于延续实施粤港澳大湾区个人所得税优惠政策的通知》（财税〔2023〕34 号），珠三角九市按内地与香港个人所得税税负差额给予补贴，且该补贴免征个人所得税；实务中，符合条件的个人实际税负被限制在约 15% 的上限。该政策目前执行至 2027 年 12 月 31 日。资格由广东省及相应城市认定，并设单人年度补贴上限（例如广东省地方细则规定每名纳税人每年最高 500 万元）。

就企业本体而言，市场准入遵循国家外资准入负面清单（2024 年版将全国限制措施压减至 29 条，制造业全面放开）；在大湾区的试点合作区——前海（深港现代服务业）、南沙（广州）、横琴（粤澳）以及河套（深港科技创新合作区）——另有进一步开放与便利。从事先进制造业、跨境服务、科技与医疗的外国中小企业，应同时对照全国负面清单与对应地方试点目录，因为区内更宽松的规则仅在区内适用。

实操落地路径

多数外国中小企业通过两扇门进入大湾区。第一扇门是香港：设立香港公司持有知识产权与区域合同，再在内地大湾区城市设立外商独资企业（WFOE）或代表机构从事生产与销售。第二扇门是在某个合作区内直接设立内地 WFOE，可享受特定行业的开放与行政便利。前海、南沙、横琴各自”错位”定位——前海侧重现代服务业，南沙侧重综合合作与航运，横琴侧重澳门经济多元——因此选址应跟随商业模式，而非笼统套用”大湾区”标签。广东还建成十余个港澳青年创新创业基地，港澳及海外青年创始人可借此获得孵化、补贴与本地采购对接。

下一步建议

  • 先确认目标行业是否在全国外资负面清单之外，再核对前海/南沙/横琴的具体试点目录，看是否有额外开放。
  • 若将在九市雇佣外国或港澳高级管理人员，尽早测算个人所得税补贴（财税〔2019〕31 号 / 〔2023〕34 号）的效益——在 2027 年前可显著降低用工综合成本。
  • 按契合度选点：服务业看前海，贸易航运看南沙，涉澳业务看横琴，研发看河套。
  • 在集团架构允许时，以香港作为区域财资、知识产权与合同枢纽，同时以内地 WFOE 承载实质经营。
  • 若需在港澳与内地间运输货物，应围绕”跨境一锁”与简化口岸模式规划海关与物流。
  • 在搬迁关键技术或专业人员前，先就职业资格互认事项咨询本地顾问。

来源

相关阅读

  • see also: 临港新片区与自贸区实操手册
  • see also: 海南人才与税收措施扩围
  • see also: 外商投资企业的税收协定待遇
Greater Bay Area / 大湾区

Greater Bay Area 2026: foreign-investment opportunities in healthcare and cross-border medical services

  • The “Hong Kong/Macao medicine pass” (港澳药械通) had approved 162 innovative drugs and devices (71 drugs, 91 devices) across 71 designated hospitals in all nine GBA cities by late April 2026, serving over 17,000 patient-visits.
    截至 2026 年 4 月底，”港澳药械通”已在九市 71 家指定医院获批 162 款创新药械（71 药品、91 器械），惠及超 1.7 万人次。
  • A January 2026 multinational-pharma GBA roundtable in Guangzhou gathered 15 global firms (J&J, Pfizer, AstraZeneca, Bayer, Novartis, AbbVie, Sanofi) and highlighted GBA as a strategic channel for foreign innovators.
    2026 年 1 月广州举办的跨国药企大湾区行座谈会汇聚 15 家跨国药企（强生、辉瑞、阿斯利康、拜耳、诺华、艾伯维、赛诺菲），凸显大湾区作为外企创新战略通道的定位。
  • Real-world study (RWS) via the medicine pass lets foreign products enter GBA within roughly six months and build evidence for national registration.
    借药械通开展真实世界研究，可使外资产品约 6 个月内进入大湾区，并为全国注册积累证据。
  • Qianhai has issued the nation’s first policy supporting Hong Kong/Macao and foreign-invested medical institutions, with 14 international medical institutions and 4,045 beds clustered there.
    前海出台全国首个支持港澳及外商医疗机构集聚发展政策，已集聚 14 家国际化医疗机构、床位 4045 张。
  • The June 2026 “Action Plan for Stabilising and Optimising Foreign Investment” expands the wholly foreign-owned hospital pilot, already covering nine localities including Guangdong and Shenzhen.
    2026 年 6 月《利用外资固稳促优行动方案》扩大外商独资医院试点，该试点已覆盖含广东、深圳在内的 9 地。
  • Cross-boundary medical data and ambulance transfer are now operational, with Shenzhen–Hong Kong medical-data channels transmitting over 6.79 million files in four months.
    跨境医疗数据与转运已落地，深港医疗数据通道上线 4 个月传输超 679 万份文件。
  • Foreign investors should enter via the medicine pass for products, the FTZ hospital pilot for services, and RWS collaboration for evidence generation.
    外资企业应通过药械通导入产品、借自贸区医院试点提供医疗服务、以真实世界研究合作生成证据。

Greater Bay Area 2026: foreign-investment opportunities in healthcare and cross-border medical services | 2026 大湾区：医疗健康产业外资机会（港澳药械通、跨境医疗服务）

Overview

Healthcare is one of the most attractive — and most regulated — sectors for foreign investors in the Greater Bay Area (GBA). Two forces converge in 2026. First, the “Hong Kong/Macao medicine pass” (港澳药械通) has matured from a regional pilot into a strategic channel that multinational innovators treat as part of their China strategy. Second, the policy environment for foreign-invested medical services — wholly foreign-owned hospitals, Hong Kong/Macao-invested institutions, cross-boundary care — is being actively widened. For a foreign healthcare group, the GBA is no longer just a sales market but a place to run clinical evidence, pilot cross-boundary care and anchor regional operations.

This article maps the 2026 opportunity across three layers: innovative drugs and devices via the medicine pass, foreign-invested and Hong Kong/Macao medical institutions, and cross-boundary medical services and data.

The medicine pass: from pilot to strategic channel

The 2026 multinational-pharma GBA roundtable, held in Guangzhou on 28 January 2026 and hosted by the Guangdong Development Reform Commission (Provincial GBA Office), brought together leaders from 15 multinationals — Johnson & Johnson, Pfizer, AstraZeneca, Bayer, Novartis, AbbVie, Sanofi and others — with Guangdong and nine-city governments. The message from firms was consistent: the GBA’s market potential and innovation ecosystem make it a strategic location, and the medicine pass is the fastest route for innovative products.

The pass has expanded sharply. The number of Hong Kong/Macao drugs and devices approved for use in the GBA rose from 48 in 2023 to 146 (another source cites 149) by early 2026, and designated medical institutions grew from 19 to 71, covering all nine GBA cities. By late April 2026 the approved total reached 162 innovative products (71 drugs, 91 devices), serving over 17,000 patient-visits. Guangdong has enacted the *Regulations of Guangdong Province on the Import of Hong Kong and Macao Drugs and Medical Devices in the Nine GBA Mainland Cities*, standardising filing and approval and raising efficiency.

For foreign innovators the decisive advantage is speed and evidence. Industry experts note that, versus the traditional registration path, products can clear the medicine-pass access process in as little as six months. Just as important, the pass supports real-world study (RWS): Guangdong has issued supporting policies allowing public hospitals to collaborate with firms on RWS and detailing the filing process. Seven multinationals have already run nine RWS projects with four GBA medical institutions. A notable case is Pfizer’s migraine drug rimegepant, whose prospective single-arm multi-centre RWS was completed in three months using Guangzhou’s rich clinical resources.

Foreign-invested and Hong Kong/Macao medical institutions

On the services side, Qianhai has issued what it describes as the nation’s first policy supporting the clustered development of Hong Kong/Macao and foreign-invested medical institutions, and is advancing a wholly foreign-owned hospital pilot. The cluster already comprises 14 international medical institutions with 4,045 beds, and overseas-patient visits grow over 10% annually. Under “talent connect”, Shenzhen’s first Hong Kong nurse registered to practise in Qianhai, six Hong Kong-style family-doctor studios opened, and 44 overseas medical experts are resident. Under “medicine connect”, the pass covers five tertiary hospitals in the cooperation zone with 60 approved items serving over 2,300 patient-visits. Under “ambulance connect”, cross-boundary transfer achieves “no-exit clearance, point-to-point direct” with transfer time cut by 80%.

The June 2026 *Action Plan for Stabilising and Optimising Foreign Investment* (MOFCOM, NDRC, MOF) explicitly supports studying and expanding the geographic scope of the wholly foreign-owned hospital pilot. The existing pilot covers nine localities — Beijing, Shanghai, Tianjin, Nanjing, Suzhou, Fuzhou, Guangdong, Shenzhen and the whole of Hainan island — and the plan signals further expansion. It also supports bringing more innovative drugs and devices into commercial insurance coverage and facilitating foreign-invested drugs into retail channels.

Cross-boundary medical services and data

Cross-boundary care is becoming operational. The University of Hong Kong–Shenzhen Hospital — a GBA cross-boundary medical benchmark — is among the first medicine-pass pilot hospitals, has introduced 34 international drugs and 18 devices serving over 7,500 patient-visits, and hosts nearly 100 Hong Kong-registered doctors. It runs a Futian port direct shuttle (one-hour cross-boundary) and has built one-stop cross-boundary diagnosis with multi-language service and direct insurance settlement.

Data and payment rails are being built. Shenzhen–Hong Kong medical-data cross-boundary security channels transmitted over 6.79 million medical files in four months. Under “payment connect”, Shenzhen’s first “medical insurance + commercial insurance” one-stop service centre supports overseas cards and digital RMB; six institutions connect to international insurers for instant settlement. Guangzhou’s ten measures on the medicine pass (issued 30 March 2026) add a quarterly Guangzhou–Hong Kong–Macao consultation mechanism, an RWS collaboration network, and support for commercial-insurance inclusion and cross-boundary electronic payment.

Practical pathways for foreign investors

  • For innovative products: treat the medicine pass as a China strategy, not a regional sideline. Identify clinical-need products already approved in Hong Kong/Macao, file through designated hospitals, and pair access with an RWS plan to generate national-registration evidence.
  • For services: use the Qianhai / Nansha / Hengqin platforms and the expanded wholly foreign-owned hospital pilot to establish or partner with international medical institutions; anchor on the “ten connect” model (institution, talent, medicine, service, ambulance, payment, data, education, guarantee, elderly care).
  • For payers and insurers: build direct-billing and commercial-insurance links; the GBA is piloting “medical insurance + commercial insurance” one-stop settlement and cross-boundary e-payment.
  • For evidence: collaborate with GBA hospitals on RWS; several multinationals already run such projects and the policy framework is explicit.
  • Compliance: the pass is bounded to designated hospitals and approved indications; products still need national registration for nationwide scale, and data crossing must follow the negative-list and security-channel rules.

Sources

Related reading

  • see also: GBA cross-boundary professional talent recognition (article 136)
  • see also: GBA foreign-invested enterprise tax and landing (article 135)
  • see also: Vocational training and education opening for foreign investors (article 138)

2026 大湾区：医疗健康产业外资机会（港澳药械通、跨境医疗服务）

概述

医疗健康是粤港澳大湾区对外资最具吸引力也最受监管的领域之一。2026 年两股力量交汇。其一，”港澳药械通”已从区域试点成熟为跨国创新者视为中国战略一部分的通道。其二，外商投资医疗服务——外商独资医院、港澳资机构、跨境医疗——的政策环境正被主动拓宽。对外资医疗集团而言，大湾区已不仅是销售市场，更是开展临床证据、试点跨境诊疗、布局区域运营的落脚点。

本文从三个层面梳理 2026 年的机会：借药械通导入创新药械、外资与港澳资医疗机构、跨境医疗服务与数据。

药械通：从试点到战略通道

2026 年 1 月 28 日在广州举行的跨国药企大湾区行座谈会，由广东省发展改革委（省大湾区办）主办，汇聚强生、辉瑞、阿斯利康、拜耳、诺华、艾伯维、赛诺菲等 15 家跨国药企高层与广东及九市政府。企业方的信号一致：大湾区市场潜力与创新生态使其成为战略要地，药械通是创新产品最快的入口。

药械通扩容迅猛。获批在粤港澳大湾区内使用的港澳药品、医疗器械，从 2023 年的 48 个增至 2026 年初的 146 个（另一说 149 个），指定医疗机构由 19 家扩展至 71 家、覆盖九市；截至 2026 年 4 月底，获批创新药械达 162 款（71 药品、91 器械），惠及超 1.7 万人次。广东已出台《广东省粤港澳大湾区内地九市进口港澳药品医疗器械管理条例》，规范申报、优化流程、提升效率。

对外资创新者，决定性优势是速度与证据。行业专家指出，相较传统注册路径，产品借药械通可在约 6 个月内完成准入；同样重要的是，药械通支持真实世界研究（RWS）——广东已出台配套政策，允许公立医院与企业合作开展 RWS 并细化申报流程。已有 7 家跨国药企与 4 家大湾区医疗机构开展 9 项真实世界研究。典型案例是辉瑞偏头痛药物瑞美吉泮，借助广州丰富医疗资源，仅三个月即完成前瞻性单臂多中心真实世界研究。

外资与港澳资医疗机构

服务端，前海出台其称为全国首个的支持港澳及外商医疗机构集聚发展政策，并推进外商独资医院试点。该集聚区已汇集 14 家国际化医疗机构、床位 4045 张，境外人士就诊量年增超 10%。在”人才通”下，深圳首名香港护士在前海注册执业，开设 6 家港式家庭医生工作室，44 名境外医疗专家常驻；”药械通”覆盖合作区内 5 家三级医院、累计获批 60 件、服务超 2300 人次；”救护通”实现”无下车通关、点对点直达”，转运时间压缩 80%。

2026 年 6 月商务部、国家发改委、财政部印发的《利用外资固稳促优行动方案》明确支持研究扩大外商独资医院试点区域范围。现有试点覆盖北京、上海、天津、南京、苏州、福州、广东、深圳及海南全岛 9 地，方案释放进一步扩围信号；同时支持将更多创新药械纳入商业保险保障、便利外资企业生产的药品进入零售渠道。

跨境医疗服务与数据

跨境诊疗正走向可运营。香港大学深圳医院作为大湾区跨境医疗标杆，是首批药械通试点医院，已引进 34 种国际药品、18 种器械，惠及超 7500 人次，近 100 名港籍医生执业；开通福田口岸直达专线（跨境单程 1 小时），构建一站式跨境诊疗、多语种服务与保险直付。

数据与支付通道正在搭建。深港医疗数据跨境安全通道上线 4 个月传输医疗文件超 679 万份；”支付通”建成深圳首家”医保+商保”一站式服务中心，支持境外卡与数字人民币，6 家机构接入国际商保实现即时结算。广州 2026 年 3 月 30 日发布的药械通”十条措施”新增穗港澳季度会商机制、真实世界研究协同网络，并支持纳入商保与拓展跨境电子支付。

外资企业的实操路径

  • 创新产品： 将药械通视为中国战略而非区域副线。识别已在港澳获批的临床急需产品，通过指定医院申报，并把准入与真实世界研究计划配对，为全国注册积累证据。
  • 医疗服务： 借助前海/南沙/横琴平台与扩围的外商独资医院试点设立或与国际化医疗机构合作，锚定”十个融通”模式（机构、人才、药械、服务、救护、支付、数据、科教、保障、养老）。
  • 支付与保险： 构建直付与商保链接；大湾区正试点”医保+商保”一站式结算与跨境电子支付。
  • 证据生成： 与大湾区医院合作开展 RWS，已有多家跨国药企落地项目，政策框架明确。
  • 合规： 药械通限定于指定医院与获批适应症；产品全国放量仍需国家注册，数据跨境须遵循负面清单与安全通道规则。

来源

相关阅读

  • 见：大湾区跨境专业人才资格互认（第 136 篇）
  • 见：大湾区外商独资企业落地与税收优惠（第 135 篇）
  • 见：外商投资职业教育与职业技能培训（第 138 篇）
Greater Bay Area / 大湾区

Greater Bay Area 2026: mutual recognition progress for Hong Kong and Macao professionals practising north

  • The GBA lawyer pilot has issued 646 practicing certificates (544 Hong Kong, 102 Macao) and covers all nine mainland GBA cities, with the pilot currently due to expire on 4 October 2026.
    大湾区律师执业试点已发出 646 张执业证书（香港 544、澳门 102），覆盖内地九市，试点目前将于 2026 年 10 月 4 日到期。
  • The 2026 GBA lawyer examination runs online registration (16–25 April), legal-training, and a written exam on 19 September in Shenzhen and Zhuhai.
    2026 年粤港澳大湾区律师执业考试实行网上报名（4 月 16–25 日）、法律知识培训与 9 月 19 日深圳珠海笔试。
  • Physician recognition under CEPA has produced 951 Hong Kong/Macao doctors with Mainland qualifications and 277 short-term practitioners, supported by a ten-point facilitation package.
    CEPA 框架下医师便利化已形成 951 名取得内地资格的港澳医生与 277 名短期执业者，并配套十条便利措施。
  • Tax agents from Hong Kong and Macao may practise in Qianhai–Shekou without an examination, by registration, and may even establish jointly-run tax-agent firms.
    港澳涉税专业人士可在前海蛇口免考试、以执业登记方式执业，并可发起设立联营税务师事务所。
  • Nansha’s 2.0 overseas professional-qualification list covers 248 qualifications (112 from Hong Kong/Macao/Taiwan) and introduces a “practise first, file later” model.
    南沙 2.0 版境外职业资格认可清单覆盖 248 项资格（含港澳台 112 项），并推出”先执业后备案”模式。
  • Foreign-invested firms should track the October 2026 pilot expiry and the possible elevation of the lawyer pilot into a permanent institution.
    外资企业应当关注 2026 年 10 月的试点到期节点，以及律师试点可能上升为法律制度安排的走向。
  • Recognised professionals still need the underlying Mainland entity, licence and social-insurance coordination before they can deliver services in Guangdong.
    获认可专业人士仍需在广东具备 underlying 内地主体、执业许可与社保衔接，方能实际提供服务。

Greater Bay Area 2026: mutual recognition progress for Hong Kong and Macao professionals practising north | 2026 大湾区：港澳专业人才北上执业资格互认进展

Overview

A recurring bottleneck for foreign-invested and Hong Kong/Macao-invested businesses in the Greater Bay Area (GBA) is talent: can the professionals they rely on — lawyers, doctors, tax agents — actually practise north of the border? The 2026 picture is one of steady, pragmatic liberalisation concentrated in three professions, each with its own mechanism. Lawyers move through a statutory pilot with an expiry date; lawyers’ recognition is the most advanced and most politicised. Doctors move through CEPA-based facilitation and the “Hong Kong/Macao medicine pass”. Tax agents move through a Qianhai–Shekou pilot that has already removed the examination barrier.

This article takes stock of where each profession stands in 2026, what the remaining conditions are, and what foreign-invested enterprises should watch.

Lawyers: a mature pilot facing a sunset clause

The GBA lawyer pilot originated from an August 2020 NPC Standing Committee authorisation allowing Hong Kong legal practitioners and Macao lawyers to obtain Mainland practicing qualifications and practise in the nine GBA mainland cities. A September 2023 decision extended the pilot by three years to 4 October 2026.

According to the State Council report deliberated at the 23rd session of the 14th NPC Standing Committee in June 2026, the Ministry of Justice has organised five GBA lawyer examinations; more than 2,000 Hong Kong and Macao lawyers registered, and 646 obtained the GBA lawyer certificate — 544 Hong Kong legal practitioners and 102 Macao lawyers. Geographically they cover all nine cities: Guangzhou 166, Shenzhen 351, Zhuhai 58, Foshan 13, Huizhou 11, Dongguan 19, Zhongshan 16, Jiangmen 6, Zhaoqing 6. Of the 646, 81 serve as arbitrators at Mainland arbitration institutions, 71 as commercial mediators, and 26 as specially-invited mediators at Guangdong courts. They practise in 190 law firms, including 106 in HK/Macao–Mainland joint-venture firms and 540 in Mainland firms.

The 2026 examination follows a clear calendar. The Ministry of Justice announcement (30 March 2026) sets online registration from 16 to 25 April, a compulsory legal-knowledge training before the exam, and the written test on 19 September in Shenzhen and Zhuhai. Two papers (objective and subjective) total 200 points; results and the pass line are published by January 2027.

A critical uncertainty is the 4 October 2026 sunset. The report notes broad support for elevating the pilot into an institutional arrangement, and stakeholders are watching whether it is extended again or codified.

Doctors: CEPA facilitation and the medicine pass

Medical recognition is broader but more layered. Under CEPA, Guangdong has rolled out a ten-point facilitation package for Hong Kong and Macao doctors — “short-term practice + multi-site practice + Hong Kong/Macao medicine pass + professional-title recognition”. By 2025, 95 Macao nursing graduates had passed the national nurse exam in Guangdong, 73 Hong Kong/Macao talents obtained professional-title assessments, 951 Hong Kong/Macao doctors had obtained Mainland physician qualifications and practise, and 277 practise short-term. Fifty Hong Kong/Macao-invested medical institutions operate in Guangdong.

For individual doctors, the Hong Kong/Macao physician qualification recognition (clinical, dental; TCM via the provincial TCM bureau) requires, among other things, lawful practice qualification in Hong Kong/Macao for at least five years before 31 December 2007, a specialist certificate, and current practice in a Hong Kong/Macao medical institution. The Guangdong government service portal shows an eight-working-day commitment for the recognition, fully online.

The “Hong Kong/Macao medicine pass” (港澳药械通) complements physician mobility: it lets specified Mainland GBA hospitals use drugs and devices already approved in Hong Kong/Macao, so a Hong Kong specialist can treat cross-boundary patients with familiar products. As of late April 2026, the pass covered 162 approved innovative drugs/devices (71 drugs, 91 devices) across 71 designated hospitals in all nine cities, serving over 17,000 patient-visits.

Tax agents: the Qianhai–Shekou breakthrough

The least visible but most procedurally radical change is for tax agents. The *Interim Measures for Hong Kong and Macao Tax Professionals Practising in the China (Guangdong) FTZ Shenzhen Qianhai–Shekou Area*, revised and issued by the Shenzhen Tax Bureau, removed the practice examination, widened eligibility from Hong Kong tax agents to Hong Kong and Macao tax professionals, dropped the 180-day practice requirement, and allowed them to establish tax-agent firms (treated as Mainland tax agents as shareholders). Registration, not examination, is the gateway.

The results are concrete: the first Hong Kong/Macao-invested tax-agent firm (Guozheng Zhengzheng) was established in Shenzhen in 2021, and the first tripartite Shenzhen–Hong Kong–Macao joint tax-agent firm (Hua Meng Ling Jun Liu Guo) was registered in Qianhai in November 2021. As of recent figures, 74 Hong Kong/Macao tax professionals have completed cross-boundary practice registration and 7 joint-venture tax-agent firms are administratively registered and operating. Supporting measures — the “18 measures for innovation in Qianshui tax-related services” and “15 measures to boost the Qianhai tax-service cluster” — have drawn the first batch of over 30 well-known tax institutions to the cluster.

Nansha’s recognition list and “practise first, file later”

Beyond the three professions, Nansha has built a broad recognition channel. Its 2.0 overseas professional-qualification list (issued January 2026) covers 248 foreign qualifications (112 from Hong Kong/Macao/Taiwan) and pairs with the *Nansha Measures for Hong Kong/Macao Professional Institutions and Professionals*. The standout innovation is “practise first, file later”: a Hong Kong/Macao-registered institution or individual with recognised qualifications may provide professional services in engineering, urban planning and medical fields in Nansha and complete confirmation within one month after practise. Nansha also recognises Hong Kong’s MPF and Macao’s social-security fund as equivalent, exempting dual social-insurance contributions for qualifying residents.

Practical implications for foreign-invested enterprises

  • Legal counsel: a foreign-invested enterprise with GBA disputes can now retain a GBA-licensed Hong Kong or Macao lawyer directly, and should brief counsel on the 4 October 2026 pilot horizon when planning multi-year engagements.
  • Medical cover: firms relocating staff to the GBA can leverage the medicine pass and cross-boundary medical facilities (e.g., the University of Hong Kong–Shenzhen Hospital) for international-standard care.
  • Tax and audit: Hong Kong/Macao-invested groups can use Qianhai-based joint tax-agent firms for integrated cross-boundary tax and audit, but must confirm the firm’s registration and the professional’s practise status.
  • Talent planning: track the lawyer-pilot sunset and the possible institutionalisation; otherwise build succession so key matters are not stranded if a licence lapses.
  • Entity and licence: recognition eases entry but does not eliminate the need for a compliant Mainland entity, local licence and social-insurance coordination.

Sources

Related reading

  • see also: GBA cross-border factor flows (article 134)
  • see also: GBA foreign-invested enterprise tax and landing (article 135)
  • see also: GBA healthcare foreign-investment opportunities (article 137)

2026 大湾区：港澳专业人才北上执业资格互认进展

概述

对外资与港澳资企业而言，粤港澳大湾区一个反复出现的瓶颈是人才：其所依赖的律师、医师、税务师能否真正跨过边境执业？2026 年的图景是务实、稳步的开放，集中于三个职业，各有机制。律师通过带有到期日的法定试点推进，其互认最成熟也最受关注；医师通过 CEPA 框架下的便利措施与”港澳药械通”流动；税务师则通过已取消考试门槛的前海蛇口试点。

本文盘点各行业 2026 年的进展、剩余条件，以及外资企业应关注的节点。

律师：成熟试点面临日落条款

大湾区律师试点源于 2020 年 8 月全国人大常委会授权，允许香港法律执业者、澳门执业律师在内地九市取得执业资质并执业；2023 年 9 月决定延长三年至 2026 年 10 月 4 日。

据 2026 年 6 月十四届全国人大常委会第二十三次会议审议的国务院报告，司法部已组织 5 次大湾区律师执业考试，2000 余名港澳律师报名，646 人取得大湾区律师执业证书——香港法律执业者 544 人、澳门执业律师 102 人。地域上覆盖九市：广州 166、深圳 351、珠海 58、佛山 13、惠州 11、东莞 19、中山 16、江门 6、肇庆 6。其中 81 人任内地仲裁机构仲裁员，71 人任商事调解员，26 人任广东各级法院特邀调解员；在 190 家律所执业，其中 106 人在港澳与内地合伙联营所、540 人在内地所。

2026 年考试日程清晰。司法部 3 月 30 日公告确定网上报名 4 月 16–25 日、考前须参加法律知识培训、9 月 19 日于深圳珠海笔试；两卷（客观+主观）共 200 分，成绩与合格线于 2027 年 1 月公布。

关键不确定性在 2026 年 10 月 4 日的日落节点。报告提到各方普遍希望将试点上升为法律制度安排，市场正关注其是否再次延期或立法固化。

医师：CEPA 便利与药械通

医师互认面更广但层级更多。CEPA 框架下，广东推出港澳医师执业便利化十条，形成”短期行医+多点执业+港澳药械通+职称认定”政策包。截至 2025 年，95 名澳门护理本科毕业生在粤通过国家护士考试，73 名港澳人才通过专业技术资格评审，951 名港澳籍医生取得内地医师资格并执业，277 名短期执业；港澳服务提供者在粤开设医疗机构 50 家。

对个体医生，港澳医师内地医师资格认定（临床、口腔；中医向省中医药局申请）要求，除其他条件外，2007 年 12 月 31 日前已取得港澳合法行医资格满 5 年、具专科医师资格证书并在港澳医疗机构执业。广东政务服务网显示该认定承诺 8 个工作日办结、全程网办。

“港澳药械通”与医师流动互补：它允许指定的内地大湾区医院使用已在港澳获批的药品与器械，使香港专科医生能以熟悉的产品跨境诊治。截至 2026 年 4 月底，药械通覆盖 71 家指定医院、162 款创新药械（71 药品、91 器械），惠及超 1.7 万人次。

税务师：前海蛇口的突破

最不显眼却程序上最激进的变化在税务师领域。深圳市税务局修订印发的《港澳涉税专业人士在中国（广东）自由贸易试验区深圳前海蛇口片区执业管理暂行办法》，取消执业考试，将适用从香港税务师扩展至香港、澳门涉税专业人士，取消 180 天执业天数要求，并允许其发起设立税务师事务所（视同内地税务师担任股东）。准入方式为执业登记而非考试。

成效具体：全国第一家港澳投资的税务师事务所（国正郑郑）2021 年在深圳设立，全国第一家深港澳联营税务师事务所（华盟灵均刘郭）2021 年 11 月在前海登记。据近期数据，已有 74 位港澳涉税专业人士完成跨境执业登记，7 家联营税务师事务所完成行政登记并实际运营。《前海涉税服务业集聚区十八条》与《助推前海涉税服务业集聚区建设十五项举措》已吸引首批 30 余家知名涉税机构签约入驻。

南沙的认可清单与”先执业后备案”

除三职业外，南沙构建了更宽的认可通道。其 2026 年 1 月发布的 2.0 版境外职业资格认可清单覆盖 248 项境外资格（含港澳台 112 项），配套《南沙区港澳专业机构和港澳专业人士执业实施办法》。突出创新是”先执业后备案”：取得港澳认可资质的机构和自然人，可在南沙工程建设、城市规划、医疗等领域提供服务，并在执业后 1 个月内完成确认。南沙还认可香港强积金、澳门社会保障基金为等效社保，对符合条件的港澳居民豁免重复参保。

对外资企业的实务启示

  • 法律顾问： 涉及大湾区争议的外资企业现在可直接聘请持大湾区执照的香港或澳门律师，并就 2026 年 10 月 4 日的试点节点，在多年期委托中提前规划。
  • 医疗覆盖： 搬迁员工至大湾区的企业，可借助药械通与跨境医疗机构（如香港大学深圳医院）获得国际水准诊疗。
  • 税务与审计： 港澳资集团可使用前海联营税务师事务所提供一体化跨境税务与审计，但须确认事务所登记状态与专业人士执业资格。
  • 人才规划： 关注律师试点日落及可能的制度化走向，否则应建立 succession，避免证照失效导致事务搁置。
  • 主体与许可： 互认降低准入门槛，但不免除合规的内地主体、本地许可与社保衔接要求。

来源

相关阅读

  • 见：大湾区跨境要素流动便利化（第 134 篇）
  • 见：大湾区外商独资企业落地与税收优惠（第 135 篇）
  • 见：大湾区医疗健康产业外资机会（第 137 篇）
Greater Bay Area / 大湾区

Greater Bay Area 2026: landing wholly foreign-owned and Hong Kong/Macao-invested enterprises, and tax preferences

  • The Qianhai 15% corporate income tax (CIT) preference has been extended through 31 December 2027 by Cai Shui [2026] No. 3, keeping Qianhai’s effective rate on par with Hong Kong.
    前海 15% 企业所得税优惠已由财税〔2026〕3 号延长至 2027 年 12 月 31 日，使前海实际税负与香港看齐。
  • Qianhai’s 15% rate applies to five broad sectors — modern logistics, information services, technology services, cultural creativity and business services — and requires “substantive operation” in the zone.
    前海 15% 税率适用于现代物流、信息服务、科技服务、文化创意、商务服务业五大类，并要求在区内”实质性运营”。
  • Nansha offers a parallel “dual 15%” package: 15% CIT for encouraged industries in the launch zone, and a full refund of the portion of Hong Kong/Macao residents’ individual tax exceeding the Hong Kong/Macao level.
    南沙提供对等的”双 15%”：先行启动区鼓励类产业企业减按 15% 征收企业所得税，港澳居民个税超港澳税负部分予以免征。
  • Hengqin extends CIT preferences to Guangdong–Macao cooperative industries, and from April 2026 Macao vehicles may enter other parts of Guangdong from Hengqin without a guarantee.
    横琴将企业所得税优惠延伸至粤澳合作产业；自 2026 年 4 月起，澳门机动车可经横琴免担保入出广东省其他区域。
  • Substantive-operation rules now use a tiered headcount test (3 to 30+ social-insured staff) and a “self-assess, commit, keep records” management model.
    实质性运营规则采用分段人数标准（3 至 30 名以上参保员工），并以”自行判定、申报承诺、留存备查”管理。
  • Foreign-invested and Hong Kong/Macao-invested enterprises should register in the right platform, model the tax saving, and prepare substantive-operation evidence before year-end.
    外资与港澳资企业应在合适的平台注册，提前测算节税效益，并在年底前备齐实质性运营佐证。
  • Nansha’s “foreign-investment stabilisation” awards can reach RMB 50 million, layered on top of the tax preferences.
    南沙”稳外资”奖励最高可达 5000 万元，与税收优惠叠加享受。

Greater Bay Area 2026: landing wholly foreign-owned and Hong Kong/Macao-invested enterprises, and tax preferences | 2026 大湾区：外商与港澳资企业落地实操与税收优惠

Overview

For a foreign or Hong Kong/Macao investor entering the Greater Bay Area (GBA), the single most consequential decision after choosing a sector is choosing a landing zone, because the GBA’s most generous tax preferences are geographically ring-fenced to three pilot platforms — Qianhai (Shenzhen–Hong Kong modern services), Nansha (Guangzhou trade and shipping) and Hengqin (Guangdong–Macao) — plus the HK–SZ Loop for R&D. Each runs its own “one zone, one policy” regime, and the preferences are real: a 15% corporate income tax (CIT) rate that brings the effective burden close to Hong Kong’s, twinned with individual income tax (IIT) subsidies for overseas high-end and urgently-needed talent.

This article explains, in practical terms, how a foreign-invested enterprise (FIE) or a Hong Kong/Macao-invested company actually lands in the GBA in 2026, what the tax preferences are, how “substantive operation” is now defined and evidenced, and what a prudent setup looks like.

Qianhai: 15% CIT extended to 2027, five eligible sectors

The Qianhai Shenzhen–Hong Kong Modern Service Industry Cooperation Zone pioneered the 15% CIT preference. In February 2026, the Ministry of Finance and the State Taxation Administration issued *Cai Shui [2026] No. 3*, extending the policy through 31 December 2027 and continuing to levy CIT at a reduced 15% rate on qualifying enterprises. The preference now covers the expanded 120.56 sq km Qianhai cooperation zone and applies to five sectors: modern logistics, information services, technology services, cultural creativity and business services.

On 9 February 2026, the Qianhai tax bureau and the Bao’an tax bureau, together with eight other departments, jointly issued an implementing announcement clarifying “substantive operation” (实质性运营). The stated intent is to stabilise market expectations while preventing empty-shell companies from improperly enjoying the preference.

What “substantive operation” now requires

Substantive operation is assessed across four dimensions — production/business, personnel, accounting and assets — all anchored in the zone:

  • Production/business in the zone: a fixed place and necessary equipment, with the main business location or the entity exercising substantive overall management and control located in Qianhai, and contracts concluded in the enterprise’s own name.
  • Personnel in the zone: employees actually working in Qianhai, paid through a bank account opened in Qianhai, with social-insurance contributions. A tiered headcount test applies: enterprises with fewer than 10 employees need at least 3 insured staff; those with 10–99 need at least 30%; those with 100+ need at least 30 insured staff for the year.
  • Accounting in the zone: accounting archives kept in Qianhai and the basic deposit account plus the main settlement account opened in Qianhai.
  • Assets in the zone: owned or used property actually employed in Qianhai and matched to the business.

The management model is “self-assess, commit, keep records”: the enterprise commits in its annual settlement, files a *Substantive Operation Self-Assessment Commitment Form*, and retains supporting documents (lease/title proof, board minutes, staff list and social-insurance evidence, accounting and bank materials, asset description). Tax authorities perform full coverage checks on new beneficiaries and proportionate spot checks on existing ones. Enterprises that merely book the zone for settlement, invoicing or tax filing without real functions are deemed non-compliant.

Nansha: the “dual 15%” package and a stabilisation award

Nansha’s preferences originate from the *Nansha Plan*. From 1 January 2022, enterprises in the Nansha launch zone in encouraged industries pay CIT at 15%; high-tech or technology SME key-industry enterprises may carry forward losses for up to 13 years; and Hong Kong/Macao residents working in Nansha receive a full refund of the IIT portion exceeding the Hong Kong/Macao tax burden.

The results are tangible. By end-November 2025, 60 enterprises had enjoyed the 15% CIT preference in Nansha, with cumulative tax relief exceeding RMB 2.1 billion; newly settled beneficiaries contributed over RMB 1.9 billion in tax and over RMB 50 billion in revenue. The Yuexiu iPark (Guangdong–Hong Kong Smart Valley) in the Qingsheng hub saw the number of Hong Kong/Macao enterprises grow fivefold in three years to over 210 registered or resident firms.

Nansha also layers a “foreign-investment stabilisation” award on top, reportedly up to RMB 50 million, requiring capital-verification and FDI-inward registration evidence. Both the 15% CIT and the awards generally run to 31 December 2026 for the current cycle, so timing matters.

Hengqin: Guangdong–Macao cooperation preferences

Hengqin applies CIT preferences to enterprises in the *Hengqin Guangdong–Macao Deep Cooperation Zone Preferential Industry Catalogue*, aligned to Macao diversification. In April 2026 the State Council approved Macao motor vehicles to enter other parts of Guangdong from Hengqin without a guarantee, and the customs authority is preparing supporting supervision measures — a concrete mobility benefit for Macao-invested operators.

Financial and talent facilitation supporting the landing

Beyond tax, the platforms ease the practical landing. In Nansha the FT account system has opened over 9,700 accounts with cross-border settlement near RMB 5 trillion, and the average time for Hong Kong-invested enterprises to complete RMB capital-account settlement was cut by over 50%. Guangzhou is accelerating the establishment of a GBA International Commercial Bank, deepening the “Nansha Finance 30 Measures”, expanding QDLP/QFLP pilots, and exploring cross-border “credit connect”. For talent, Nansha’s upgraded overseas professional-qualification recognition lists (2.0 version) cover 248 foreign professional qualifications (including 112 from Hong Kong/Macao/Taiwan) and offer rewards up to RMB 1 million for qualified holders, with a “practise first, file later” model in engineering, urban planning and medical fields.

Practical landing path

Most foreign and Hong Kong/Macao investors enter through one of two doors. Door one is Hong Kong: incorporate a Hong Kong company to hold IP, regional contracts and treasury, then set up a WFOE or branch in a GBA mainland platform. Door two is a direct Mainland WFOE inside Qianhai, Nansha or Hengqin, capturing the platform-specific tax and facilitation benefits. The choice should follow the business model: services and Hong Kong linkage favour Qianhai; trade, shipping and FT treasury favour Nansha; Macao-linked activity favours Hengqin.

What to do next

  • Confirm your sector is off the national negative list, then check the specific Qianhai / Nansha / Hengqin preferential catalogue for sector fit (main business revenue generally must exceed 60% of total revenue for the preference).
  • Model the 15% CIT saving early — for a profitable modern-services or technology enterprise the saving versus the standard 25% rate is material through 2027 (Qianhai) and ongoing (Nansha/Hengqin by their own terms).
  • Build substantive-operation substance before year-end: lease space, open the settlement account in the zone, relocate or hire the required insured headcount, and keep board and accounting records in the zone.
  • If employing Hong Kong/Macao or foreign senior staff, layer the IIT subsidy / refund on top of the CIT preference.
  • Track the 31 December 2026 deadlines for Nansha’s current award and preference cycle and plan capital injection and filing accordingly.

Sources

Related reading

  • see also: GBA cross-border factor flows (article 134)
  • see also: GBA cross-boundary professional talent recognition (article 136)
  • see also: GBA healthcare foreign-investment opportunities (article 137)

2026 大湾区：外商与港澳资企业落地实操与税收优惠

概述

对进入粤港澳大湾区（GBA）的外国或港澳投资者而言，选定行业之后最关键的决策就是选址，因为大湾区最优惠的税收待遇在地理上被限定在前海（深港现代服务业）、南沙（广州贸易航运）、横琴（粤澳）以及研发导向的河套四大平台之内。各平台实行”一区一策”，而优惠是实打实的：15% 的企业所得税率让实际税负接近香港，叠加面向境外高端紧缺人才的个人所得税补贴。

本文以实务视角说明，外资企业或港澳资公司在 2026 年如何实际落地大湾区、税收优惠有哪些、”实质性运营”如何界定与举证，以及稳健的架构应如何设计。

前海：15% 企业所得税延至 2027 年，五大类适用

前海深港现代服务业合作区最早推出 15% 企业所得税优惠。2026 年 2 月，财政部、税务总局印发《关于延续实施前海深港现代服务业合作区企业所得税优惠政策的通知》（财税〔2026〕3 号），将政策执行期限延长至 2027 年 12 月 31 日，继续对符合条件的企业减按 15% 税率征收。优惠现已覆盖扩区后的 120.56 平方公里前海合作区全域，适用五大类产业：现代物流、信息服务、科技服务、文化创意、商务服务业。

2026 年 2 月 9 日，前海税务局与宝安区税务局等 8 部门联合发布公告，明确”实质性运营”的具体标准，意在稳定市场主体预期、防止空壳公司违规享受优惠。

“实质性运营”的当前要求

实质性运营从生产经营、人员、账务、财产四个维度在区内判定：

  • 生产经营在区内： 拥有固定场所与必要设备，主要生产经营地点或实施实质性全面管理的机构在区内，并以本企业名义对外订立合同。
  • 人员在区内： 在区内有满足需要的从业人员实际工作，工资薪金经区内银行账户发放并缴纳社保；分段人数标准：不满 10 人的企业至少 3 名参保员工，10–99 人的至少 30%，100 人以上的至少 30 名参保员工。
  • 账务在区内： 会计档案存于区内，基本存款账户与主营结算账户开立在区内。
  • 财产在区内： 企业拥有或使用的财产在区内实际运用，并与经营相匹配。

管理采取”自行判定、申报承诺、留存备查”：企业在年度汇算清缴时承诺并填写《实质性运营自评承诺表》，留存租赁合同、决策会议纪要、员工名单与社保证明、账务与开户资料、财产说明等。税务机关对当年新增享受企业全覆盖核查，对存量企业按比例抽查。仅承担区外业务结算、开票、申报而无实际功能的企业，视为不符合。

南沙：”双 15%”与稳外资奖励

南沙优惠源自《南沙方案》。自 2022 年 1 月 1 日起，南沙先行启动区鼓励类产业企业减按 15% 征收企业所得税；高新技术重点行业企业亏损结转最长延至 13 年；在南沙工作的港澳居民，其个税税负超过港澳税负的部分予以免征。

成效显著。截至 2025 年 11 月底，南沙已有 60 户企业享受鼓励类产业 15% 优惠，累计减免税额超 21 亿元；新落户享惠企业贡献税收超 19 亿元、营收超 500 亿元。庆盛枢纽片区的越秀 iPark 粤港智谷，港澳企业三年增长 5 倍至超 210 家。

南沙还叠加”稳外资”奖励，据称最高 5000 万元，需提供验资报告与 FDI 入账登记证明。15% 企业所得税与奖励在当前周期一般执行至 2026 年 12 月 31 日，时点很关键。

横琴：粤澳合作优惠

横琴对《横琴粤澳深度合作区企业所得税优惠目录》内企业给予企业所得税优惠，对接澳门经济多元。2026 年 4 月，国务院批复同意澳门机动车经横琴免担保入出广东省其他区域，海关正制定配套监管办法——这是澳门资运营者的切实流动红利。

支撑落地的金融与人才便利

除税收外，平台还降低落地摩擦。南沙 FT 账户体系累计开立超 9700 户，跨境结算近 5 万亿元，港资企业人民币资本金入账结算平均耗时缩减 50% 以上。广州正加快筹设大湾区国际商业银行，落实”南沙金融 30 条”，拓展 QDLP/QFLP 试点，探索”征信通”。人才方面，南沙升级版境外职业资格认可清单（2.0）覆盖 248 项境外职业资格（含港澳台 112 项），符合条件的持证人才最高奖励 100 万元，并在工程建设、城市规划、医疗等领域实行”先执业后备案”。

实操落地路径

多数外资与港澳资投资者通过两扇门进入：第一扇门是香港——设立香港公司持有知识产权、区域合同与财资，再在内地大湾区平台设 WFOE 或分公司；第二扇门是在前海、南沙或横琴直接设立内地 WFOE，享受平台专属税收与便利。选择应跟随商业模式：服务业与港联动看前海，贸易航运与 FT 财资看南沙，涉澳业务看横琴。

下一步建议

  • 先确认目标行业不在全国外资负面清单，再对照前海/南沙/横琴具体优惠目录判断契合度（优惠通常要求主营业务收入占比超 60%）。
  • 尽早测算 15% 企业所得税节税：对盈利的现代服务业或科技企业，相较 25% 标准税率的节省在 2027 年前（前海）及持续（南沙/横琴各自期限内）都相当可观。
  • 年底前构建实质性运营：区内租赁场所、开立结算账户、迁移或雇佣所需参保人数、账务与决策记录留存在区。
  • 若雇佣港澳或外籍高管，在 CIT 优惠之上叠加 IIT 补贴/退还。
  • 关注南沙当前奖励与优惠周期 2026 年 12 月 31 日的节点，相应安排注资与申报。

来源

相关阅读

  • 见：大湾区跨境要素流动便利化（第 134 篇）
  • 见：大湾区跨境专业人才资格互认（第 136 篇）
  • 见：大湾区医疗健康产业外资机会（第 137 篇）
Greater Bay Area / 大湾区

Greater Bay Area 2026: new facilitation for cross-border flow of people, goods and capital

  • In May 2026 the General Administration of Customs issued a 20-measure package specifically designed to accelerate the flow of goods, people and data across the Guangdong–Hong Kong–Macao Greater Bay Area.
    2026 年 5 月，海关总署出台包含 20 项具体举措的一揽子政策，专门推动粤港澳大湾区货物、人员与数据的跨境流动。
  • The “single declaration, dual application” model cuts declaration time by roughly half, while the expanded “cross-boundary lock” compresses cargo clearance time by about 30%.
    “一单两报”模式将申报时间缩短约一半，”跨境一锁”范围扩大后货物运输通关时长压缩约 30%。
  • Cross-border wealth management connect (WMC), the integrated local/foreign-currency cash pool and the FT account system remain the three pillars channelling foreign-investor capital across the GBA.
    跨境理财通、本外币一体化资金池与 FT 账户体系，仍是引导外资资金在大湾区跨境流动的三大支柱。
  • Goods flows benefit from “combined port” and multi-modal pilots, with cross-border e-commerce “inspect first, ship later” lowering logistics cost by about 30%.
    货物流动受益于”组合港”与多式联运试点，跨境电商”先查验、后装运”使物流成本降低约 30%。
  • Guangdong is advancing “Guangdong vehicles going south” and “Greater Bay Area yacht free travel”, and broadening mutual recognition of professional qualifications for Hong Kong and Macao residents.
    广东正推进”粤车南下”与”粤港澳游艇自由行”，并扩大港澳居民职业资格互认范围。
  • A pilot negative list for cross-border data export is being rolled out in the Guangdong FTZ, and Shenzhen–Hong Kong medical-data sharing is being trialled.
    广东自贸试验区正在落地数据出境负面清单试点，深港医疗数据跨境共享亦在开展试点。
  • Foreign investors should map their people, goods and treasury flows onto the four major platforms — Qianhai, Nansha, Hengqin and the HK–SZ Loop — each with its own “one zone, one policy” regime.
    外国投资者应将其人员、货物与财资流动对应到前海、南沙、横琴、河套四大平台，各平台均实行”一区一策”。

Greater Bay Area 2026: new facilitation for cross-border flow of people, goods and capital | 2026 粤港澳大湾区：人流物流资金流对外资便利化新举措

Overview

The Guangdong–Hong Kong–Macao Greater Bay Area (GBA) is built on “one country, two systems, three customs territories, three legal systems”. Hong Kong and Macao are separate customs territories with their own currencies and legal traditions, while the nine Guangdong municipalities sit inside the Mainland customs and legal system. For a foreign investor, the GBA is therefore not a single frictionless market but a layered platform where the real value lies in “soft connectivity” (规则衔接、机制对接) — building bridges between the three systems so that production factors move more efficiently while each side keeps its own regime.

In 2026, against the backdrop of the “15th Five-Year Plan” opening year, the facilitation agenda has shifted from broad statements to concrete, operational measures. The most important development is the *Measures by the Customs Administration to Support the Development of the Guangdong–Hong Kong–Macao Greater Bay Area*, announced at a Guangzhou press conference on 21 May 2026, which sets out 20 specific measures across five dimensions. Complementing it are Guangdong provincial measures on infrastructure and rules, and Shenzhen’s 21-point business-environment action plan tied to the 2026 APEC ministers’ meeting. Together they materially lower the friction foreign-invested enterprises face when moving people, goods, capital and data across the GBA.

The May 2026 customs package: 20 measures in five dimensions

The 20 measures are organised around five themes: (1) integrated market development through rules alignment; (2) a science-and-innovation highland enabling efficient allocation of innovation factors; (3) new forms and models empowering foreign trade innovation; (4) a “dual circulation” logistics hub; and (5) pilot platforms such as Qianhai, Nansha, Hengqin and the HK–SZ Loop.

On trade performance, the context is strong: in 2025 the nine GBA mainland cities recorded total import–export value exceeding RMB 9 trillion; in the first four months of 2026 the figure reached RMB 3.4 trillion, up 18.4% year on year, contributing one quarter of the national increment in foreign trade. Port container throughput across the nine cities exceeds 60 million TEU annually, among the highest in the world.

Concrete customs innovations include:

  • “Single declaration, dual application” (一单两报): enterprises declare once and the data is applied on both sides, cutting declaration time by about half.
  • Expanded “cross-boundary lock” (跨境一锁): a single intelligent lock manages the whole journey, compressing cargo clearance time by roughly 30%.
  • “One-zone-one-policy” (一区一策): Qianhai, Nansha, Hengqin and the Loop each receive tailored customs support.
  • Unified GBA trade statistics: mainland customs will jointly compile and publish external goods-trade statistics for the GBA as a whole with Hong Kong and Macao customs, replacing the current patchwork of three separate datasets.

People flow: smoother movement and talent mobility

People movement is the most visible dividend. The GBA’s Hong Kong–Macao and Guangdong–Macao ports handle nearly 500 million passenger crossings per year, over 70% of the national total. The 2026 measures promote “one-stop” supervision for “Hong Kong/Macao vehicles going north” and “Guangdong vehicles going south”, and “AI +” driven “seamless customs clearance” to build a one-hour living circle.

On 29 May 2026, the Guangdong Development Reform Commission confirmed it will steadily advance “Guangdong vehicles going south” and “Greater Bay Area yacht free travel”, optimise personnel visa policies, expand the “Bay Area standard” and “Bay Area certification” regimes, and broaden mutual recognition of professional qualifications so that Hong Kong and Macao professionals can practise more easily in Guangdong. It also pledged to extend the “Hong Kong–Macao medicine and device pass” (港澳药械通), the “elderly health voucher” (长者医疗券) and the “Guangdong residential care service scheme” (广东院舍照顾服务计划).

For foreign (non-Chinese) staff, Shenzhen’s 2026 business-environment plan offers concrete entry facilitation: foreign senior managers establishing branches or subsidiaries in the Qianhai–Shekou free-trade片区 may obtain visas or residence permits valid up to two years, extended to accompanying spouses and family; AEO enterprises and trade headquarters enjoy relaxed APEC business travel card requirements; and urgent-entry port visas are available for critical foreign technical or management personnel.

Goods flow: ports, locks and bonded innovation

Goods benefit from three linked reforms. First, the “combined port / one-port-connect” (组合港 / 一港通) model and multi-modal (sea–rail, sea–sea) pilots let cargo move “one declaration, one document through”. Second, cross-border e-commerce “inspect first, ship later” (先查验、后装运) lowers logistics cost by about 30%. Third, for innovation factors, the package supports an expanded “positive list” for research materials, applies bonded supervision to imported inputs used in biomedical R&D, simplifies documentation, and explores lifecycle carbon-footprint management at customs clearance.

Agricultural and food supplies also see facilitation: a “product list + enterprise whitelist + risk monitoring” model for short-shelf-life foods destined for Hong Kong and Macao reduces on-site inspection frequency, while the “batch inspection” reform for export agri-food cuts on-site work by over 70%.

Capital flow: WMC, cash pools and FT accounts

The financial arteries are the most relevant for foreign treasury operations. Three instruments stand out:

  1. Cross-boundary Wealth Management Connect (跨境理财通): launched in 2021 and optimised in January 2024 (broader investor eligibility, securities firms included, wider product scope, higher quotas), it provides a closed-loop RMB channel for retail investors to hold cross-boundary investment accounts. Shenzhen’s 2026 plan goes further by allowing a three-party online communication channel (investor–HK/Macao seller–Mainland partner) inside pilot outlets, moving WMC from “limited contact” to “precision service”.
  2. Integrated local/foreign-currency cash pool (本外币一体化资金池): Shenzhen is deepening the pilot, bringing more qualified multinational groups into the scheme to centrally manage cross-border funds on a real-business basis.
  3. FT accounts: in Nansha, the free-trade account system had opened over 9,700 accounts with cross-border settlement approaching RMB 5 trillion, and the average time for Hong Kong-invested enterprises to complete RMB capital-account settlement was cut by more than 50%.

QFLP and QDLP pilots continue to widen: Guangdong’s QDLP quota approvals reached RMB 12.6 billion across nine institutions in the 14th Five-Year period, and over 500 foreign-invested QFLP projects were approved with quotas exceeding RMB 50 billion.南沙’s FT全功能资金池 exceeds 260 entities with FT loans above RMB 240 billion.

Data flow: negative lists and medical-data pilots

Data is the newest frontier. Shenzhen’s plan commits to issuing the China (Guangdong) Free Trade Zone negative list for cross-border data export, giving enterprises a clear, operable compliance reference. It also deepens the Shenzhen–Hong Kong cross-border data verification platform (targeting no fewer than 10 application scenarios) and pilots Shenzhen–Hong Kong medical-data sharing by connecting hospitals to Hong Kong’s “eHealth” system for mutual recognition of laboratory and imaging results.

Practical steps for foreign investors

  • Map your flows: decide whether your bottleneck is people, goods, capital or data, then identify the single measure that removes it.
  • Choose a platform by fit: Qianhai for modern services, Nansha for trade/shipping and FT treasury, Hengqin for Macao-linked activity, the Loop for R&D.
  • Use Hong Kong as a holding, financing and IP base while operating a Mainland WFOE for substance; plan treasury around WMC, the cash pool and FT accounts.
  • For R&D importers, apply the bonded-supervision and positive-list facilities for biomedical and high-tech inputs.
  • Engage a local adviser early on data-export compliance before moving operational systems across the border.

Sources

Related reading

  • see also: Greater Bay Area SME opportunities (article 22)
  • see also: GBA foreign-invested enterprise tax and landing (article 135)
  • see also: Cross-boundary talent recognition (article 136)

2026 粤港澳大湾区：人流物流资金流对外资便利化新举措

概述

粤港澳大湾区以”一个国家、两种制度、三个关税区、三种法律体系”为基础。香港、澳门是独立的关税区，拥有各自的货币与法律传统；广东九市则处于内地关境与法律体系之内。对外国投资者而言，大湾区并非一个无摩擦的统一市场，而是一个分层平台，真正的价值在于”规则衔接、机制对接”——在三套制度之间架设桥梁，让生产要素更高效地流动，同时各自保留自身制度。

2026 年，”十五五”开局之年，便利化议程已从宽泛表述转向具体可操作的举措。最重要的进展是海关总署于 2026 年 5 月 21 日在广州新闻发布会上公布的《海关支持粤港澳大湾区建设若干措施》，从五个方面提出 20 项具体举措。与之配套的是广东省在基础设施与规则衔接方面的举措，以及深圳市围绕 2026 年 APEC 会议制定的 21 条营商环境行动方案。三者共同显著降低了外资企业在大湾区跨境调动人员、货物、资金与数据时面临的摩擦。

2026 年 5 月海关一揽子政策：五个维度的 20 项举措

这 20 项举措围绕五个主题展开：（1）通过规则对接促进市场一体化；（2）打造科创高地、高效配置创新要素；（3）以新业态新模式赋能外贸创新；（4）建设”双循环”物流枢纽；（5）前海、南沙、横琴、河套等重大平台的先行先试。

从贸易表现看，背景十分强劲：2025 年大湾区内地九市进出口总值突破 9 万亿元；2026 年前 4 个月达 3.4 万亿元，同比增长 18.4%，贡献了全国外贸增量的四分之一。九市港口集装箱年吞吐量超过 6000 万标箱，居全球前列。

具体的海关创新包括：

  • “一单两报”： 企业一次申报、两地适用，申报时间缩短约一半。
  • 扩大”跨境一锁”： 单一智能锁管全程，货物运输通关时长压缩约 30%。
  • “一区一策”： 前海、南沙、横琴、河套各自获得量身定制的海关支持。
  • 统一大湾区贸易统计： 内地海关将联合港澳海关编制并发布以大湾区为整体的对外货物贸易统计数据，取代当前三套分立的数据。

人员流动：通行更顺畅、人才更便捷

人员往来是最直观的红利。粤港澳口岸年出入境人员近 5 亿人次，占全国七成以上。2026 年举措对”港车北上””澳车北上””粤车南下”实施”一站式”监管，并以”人工智能+”推动”无感通关”，助力打造”一小时生活圈”。

2026 年 5 月 29 日，广东省发展改革委确认将稳步推进”粤车南下”与”粤港澳游艇自由行”，优化人员往来签注政策，拓展”湾区标准””湾区认证”应用场景，并进一步扩大职业资格互认，便利港澳专业人士跨境在粤执业；同时扩大”港澳药械通””长者医疗券””广东院舍照顾服务计划”适用范围。

对外国（非华裔）员工，深圳 2026 年营商环境方案提供了切实的入境便利：在中国（广东）自由贸易试验区深圳前海蛇口片区筹建分公司或子公司的外国企业高级管理人员，可获 2 年以内有效签证或居留许可，并惠及配偶与家属；AEO 企业、贸易型总部企业人员申请 APEC 商务旅行卡可豁免或放宽限制；有紧急入境需求的外籍高管、技术人员可申办口岸签证。

货物流动：口岸、锁链与保税创新

货物受益于三项联动改革。其一，”组合港/一港通”模式与海铁、水水多式联运试点，让货物”一次申报、一单贯通”。其二，跨境电商”先查验、后装运”降低物流成本约 30%。其三，针对创新要素，政策扩大科研用物资”正面清单”，对生物医药研发进口料件实施保税监管、简化单证，并探索口岸通关环节碳足迹全生命周期管理试点。

农食产品供应同样得到便利：”产品清单+企业白名单+风险监测”模式面向供港澳短保质期食品降低口岸查检频次；出口农食产品”批次检验”改革减少 70% 以上现场作业。

资金流动：理财通、资金池与 FT 账户

金融血脉对外资财资运作最为关键，三项工具尤为突出：

  1. 跨境理财通： 2021 年推出，2024 年 1 月优化（扩大投资者准入、纳入证券公司、拓宽产品范围、提高额度），提供零售投资者跨境持有投资账户的闭环人民币通道。深圳 2026 年方案进一步允许在试点网点内建立”内地投资者—港澳销售机构—内地合作机构”或反向的三方线上沟通渠道，推动跨境理财从”有限接触”走向”精准服务”。
  2. 本外币一体化资金池： 深圳深化试点，将更多符合条件的跨国公司集团纳入，在真实业务背景下集中运营跨境资金。
  3. FT 账户： 南沙 FT 账户体系已累计开立超 9700 户，办理跨境结算规模近 5 万亿元；港资企业人民币资本金入账结算平均耗时缩减 50% 以上。

QFLP 与 QDLP 试点持续扩容：广东”十四五”期间 QDLP 备案机构 9 家、额度 126 亿美元，QFLP 获批项目超 500 亿元。南沙 FT 全功能资金池超 260 个、FT 项下贷款超 2400 亿元。

数据流动：负面清单与医疗数据试点

数据是最新的前沿。深圳方案承诺推动中国（广东）自由贸易试验区数据出境管理负面清单出台，为企业数据跨境流动提供清晰、可操作的合规指引；同时深化深港跨境数据验证平台应用（目标不少于 10 个场景），并试点深港医疗数据跨境共享，连接香港”医健通”系统实现检验结果互认。

外资企业的实操步骤

  • 梳理自身流动瓶颈：判断堵点在人、货、资金还是数据，再锁定单项可破局的举措。
  • 按契合度选平台：服务业看前海，贸易航运看南沙，涉澳业务看横琴，研发看河套。
  • 以香港为控股、融资与知识产权基地，同时以内地 WFOE 承载实质经营；围绕理财通、资金池与 FT 账户规划财资。
  • 研发进口企业，善用生物医药与高新技术料件的保税监管与正面清单便利。
  • 在跨境迁移业务系统前，就数据出境合规提前咨询本地顾问。

来源

相关阅读

  • 见：大湾区中小企业机遇（第 22 篇）
  • 见：大湾区外商独资企业落地与税收优惠（第 135 篇）
  • 见：跨境人才资格互认（第 136 篇）
Healthcare & Pharma / 医药医疗

Pharma opening measures under the 2026 action plan

  • The 2026 action plan supports rules for drug segmented manufacturing to facilitate overseas marketing-authorisation holders in cross-border segmented production.
    2026年行动方案支持出台药品分段生产细则，便利境外药品上市许可持有人开展跨境分段生产。
  • Pilot regions for biotechnology and wholly-foreign-owned hospitals will be further expanded.
    生物技术、外商独资医院开放试点区域将进一步扩大。
  • Insurers are encouraged to cover more innovative drugs and devices, and quality innovative products are brought into the retail channel.
    支持保险公司将更多创新药械纳入商业保险，推动优质创新药械进入零售渠道。
  • These are pharma-opening measures under the “stabilizing foreign investment” plan, complementing the general healthcare/pharma market-access brief.
    上述为”固稳促优”方案下的医药开放举措，与通用的医药医疗准入综述互为补充。
  • Eligibility and pilot regions are announced by the drug regulator and pilot-region authorities.
    资格与试点区域由药品监管及试点地区主管部门发布。
  • FIEs should assess segmented-manufacturing and hospital-pilot eligibility against their China strategy.
    外资企业应结合自身中国战略，评估分段生产与人独资医院试点的适用性。

Pharma opening measures under the 2026 action plan | 医药产业开放新措施

Overview

As part of the Action Plan for Stabilizing and Improving Foreign Investment (利用外资固稳促优行动方案), China is advancing a set of pharma and healthcare opening measures (issued 16 June 2026, 商资发〔2026〕97号; effective from 1 July 2026). These refine and extend the market-access path for foreign pharma and medtech companies, sitting alongside the general healthcare/pharma market-access framework.

This article focuses on the pharma-specific openings and is intended as a complement to the broader “Healthcare & pharma market access” brief.

Informational guidance only; exact eligibility and pilot regions are set by the drug regulator (NMPA) and pilot authorities, so verify before acting.

Measures at a glance

Drug segmented manufacturing

  • Study and issue rules for drug segmented manufacturing (药品分段生产实施细则).
  • Facilitate overseas marketing-authorisation holders (MAH) in conducting cross-border segmented manufacturing of biologics and chemical drugs.
  • Allows foreign MAHs to split the manufacturing process across sites/jurisdictions under defined rules, supporting flexible global supply.

Biotech and wholly-foreign-owned hospital pilots

  • Expand pilot regions for biotechnology and wholly-foreign-owned hospitals (外商独资医院).
  • Build an industry collaboration platform to help foreign-invested enterprises’ drugs enter the retail channel.

Insurance coverage and retail access

  • Encourage insurers to include more innovative drugs and devices in commercial insurance coverage.
  • Continuously encourage quality innovative drugs and devices to enter the China market.

How it relates to the broader access brief

  • The general Healthcare & pharma market access article covers NMPA registration, licensing and the baseline path for foreign pharma/medtech entry.
  • This brief covers the 2026 policy increments — segmented manufacturing, expanded pilots, and insurance/retail access — that lower specific frictions for foreign players.
  • Read both: the access brief for the baseline; this brief for the newest openings.

What to do next

  • Foreign MAHs: assess whether segmented manufacturing fits your supply chain and watch for the implementing rules and eligible sites.
  • Medtech/pharma groups: track expanded biotech and wholly-foreign-owned hospital pilot regions for location and eligibility.
  • Market-access teams: engage insurers and retail channels early to plan commercial-insurance and retail access for innovative products.
  • Coordinate with the drug regulator (NMPA) and pilot-region authorities on eligibility and application windows.
  • Combine this brief with the general market-access article when building your China pharma entry plan.

Sources

  • 中华人民共和国中央人民政府（国务院）— 《利用外资固稳促优行动方案》全文：https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国家药品监督管理局（官方门户）— https://www.nmpa.gov.cn
  • 商务部 — 关于印发《利用外资固稳促优行动方案》的通知（商资发〔2026〕97号）：https://tradeinservices.mofcom.gov.cn/article/zcfb/zcfg/202606/183553.html

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入（药监局）
  • see also: Stabilizing Foreign Investment Action Plan: 15 measures at a glance / 利用外资固稳促优行动方案：15条举措总览

医药产业开放新措施

概述

作为《利用外资固稳促优行动方案》的一部分，中国推进一组医药与医疗开放举措（2026年6月16日印发，商资发〔2026〕97号；自2026年7月1日起落地）。这些举措细化并延伸了外资医药与医疗器械企业的准入路径，与通用的医药医疗准入框架并行。

本文聚焦医药专项开放，旨在作为更广泛”医疗医药准入”综述的补充。

本文仅为信息性指引；具体资格与试点区域由药品监管（NMPA）及试点主管部门规定，行动前请核实。

举措一览

药品分段生产

  • 抓紧研究出台药品分段生产实施细则。
  • 便利境外药品上市许可持有人（MAH）开展生物制品、化学药品的跨境分段生产。
  • 在既定规则下，允许境外 MAH 将生产环节跨场地/辖区拆分，支撑灵活的全球供应。

生物技术与人独资医院试点

  • 扩大生物技术与外商独资医院开放试点区域。
  • 搭建行业协作平台，便利外资企业生产的药品进入零售渠道。

商保覆盖与零售可及

  • 支持保险公司将更多创新药械纳入商业保险保障范围。
  • 持续鼓励优质创新药械进入中国市场。

与通用准入综述的关系

  • 通用的医疗医药准入文章涵盖 NMPA 注册、许可及外资医药/器械来华的基线路径。
  • 本文涵盖2026年政策增量——分段生产、试点扩围、商保与零售可及——即降低外资特定摩擦的举措。
  • 两篇对照阅读：准入综述看基线，本文看最新开放。

下一步建议

  • 境外 MAH：评估分段生产是否契合供应链，关注实施规则与合格场地。
  • 医疗器械/医药集团：跟踪生物技术与人独资医院试点扩围的区域与资格。
  • 市场准入团队：尽早对接保险与零售渠道，规划创新产品的商保与零售可及。
  • 就资格与申报窗口，与药品监管（NMPA）及试点地区主管部门协同。
  • 制定中国医药入华方案时，将本文与通用准入综述结合使用。

来源

  • 中华人民共和国中央人民政府（国务院）— 《利用外资固稳促优行动方案》全文：https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国家药品监督管理局（官方门户）— https://www.nmpa.gov.cn
  • 商务部 — 关于印发《利用外资固稳促优行动方案》的通知（商资发〔2026〕97号）：https://tradeinservices.mofcom.gov.cn/article/zcfb/zcfg/202606/183553.html

相关阅读

  • see also: 医疗医药准入（药监局） / Healthcare & pharma market access (NMPA)
  • see also: 利用外资固稳促优行动方案：15条举措总览 / Stabilizing Foreign Investment Action Plan: 15 measures at a glance
Healthcare & Pharma / 医药医疗

Healthcare & pharma market access (NMPA)

  • Market access hinges on NMPA registration, not foreign approval — an FDA/EMA licence does not register a product in China.
    市场准入关键在于NMPA注册而非境外批准——FDA或EMA许可并不等于在中国注册。
  • Imported drugs and devices need a registered China responsible agent to serve as the domestic Marketing Authorisation Holder stand-in with real lifecycle duties.
    进口药品与器械须有登记的境内责任代理人，作为境内上市许可持有人的代位人，承担真实的全生命周期职责。
  • Clinical trials must follow Chinese GCP with NMPA approval and generally use local sites and Chinese patient populations; overseas data alone may be rejected.
    临床试验须遵循中国GCP并取得NMPA批准，通常须设国内研究中心并纳入中国患者人群；仅境外数据可能被拒。
  • Medical devices are tiered Class I/II/III; overseas manufacturers of Class II/III devices must register their production site with the NMPA.
    医疗器械按风险分一/二/三类；二类、三类境外生产企业须向NMPA登记其生产场地。
  • The NRDL and Volume-Based Procurement (VBP) are the dominant commercial gateways, with VBP tenders cutting prices by often 50%–90%.
    《国家医保药品目录》与集中带量采购（VBP）是主导性商业关口，VBP中标常以50%–90%的降价换取约定采购量。
  • Approved products require Chinese labels and package inserts, and import clearance hinges on the NMPA registration certificate as a key document.
    获批产品须配中文标签与说明书，进口清关以NMPA注册证作为关键单证。

Healthcare & pharma market access (NMPA) | 医疗医药准入（药监局）

Overview

Pharmaceuticals and medical devices are among the most heavily regulated products in China, supervised primarily by the National Medical Products Administration (NMPA). Market access hinges on registration, not merely on foreign approval: a drug or device lawfully sold in the EU or US generally cannot be marketed in China until it has gone through China’s own registration pathway and met Chinese standards.

This article explains the drug and device registration routes, clinical-trial requirements, and the practical steps a foreign pharma or medtech company should plan for. It is informational and must not be treated as regulatory or legal advice; confirm current requirements with the NMPA and qualified PRC counsel.

The NMPA and the marketing-authorisation-holder system

The NMPA (www.nmpa.gov.cn; English: english.nmpa.gov.cn) oversees drugs, medical devices, and cosmetics nationwide, supported by its centres for drug evaluation (CDE), medical-device evaluation (CMDE), and inspection. China operates a Marketing Authorisation Holder (MAH) system: the holder — which may be a domestic entity or, for imported products, the overseas manufacturer represented by a China responsible agent — bears the lifecycle responsibilities for a product. Foreign companies therefore need a registered China agent to act as the domestic responsible party for imported drugs and devices.

The MAH’s responsibilities are not limited to winning approval; they extend across the product’s life — pharmacovigilance and adverse-drug-reaction monitoring, post-market studies and risk-management plans, lot-release and traceability, and recall execution. For imported products, the China responsible agent stands in for the overseas MAH on these duties and can be held directly accountable by the NMPA for quality and safety failures in the China market. This makes agent selection a governance decision, not a paperwork one: the agent must have the regulatory capacity, quality-system interface, and personnel to discharge obligations such as timely adverse-event reporting and recall coordination. A weak agent is a recurring root cause of post-market enforcement actions.

Drug registration pathways

Chemical drugs are classified into five categories (Class 1 innovative, through Classes 2–5 for modified, generic, and imported/domestic equivalents), and biological products follow a parallel framework. A new innovative drug (Class 1) requires full non-clinical and clinical data generated to Chinese Good Clinical Practice (GCP) and Good Laboratory Practice standards. Generic drugs rely on bioequivalence and quality-consistency studies. Imported drugs are registered through the NMPA’s drug-evaluation centre, with dossiers submitted in the required CTD-style format and, for most new drugs, via the marketing-authorisation application after a completed clinical trial approved by the NMPA.

Clinical-trial requirements

Before a human trial in China, the sponsor must obtain NMPA approval (or, for certain listed trials, file a notification) and register the trial in the national drug-trial registration system. Trials must follow Chinese GCP; ethical review by a qualified institutional review board is mandatory, and the use of Chinese patient populations and sites is generally expected so that the data are relevant to the China population. The NMPA has, in recent years, aligned many technical guidelines with ICH standards to ease multinational, multi-regional trials, but local relevance and NMPA acceptance of overseas data still require careful planning.

A related point is the use of the communication channels (Pre-IND and formal communication meetings) with the CDE. The NMPA encourages sponsors to consult the centre at key milestones — before an IND for innovative drugs, on pivotal technical questions, and before the marketing-authorisation application. Meaningful communication materially reduces the risk of later demands for supplementary studies. For overseas-approved drugs that are clinically urgent and not yet marketed in China, conditional approval and priority-review pathways can shorten time-to-market, but they are conditioned on a commitment to complete confirmatory trials. Where overseas data are used for China registration, a racial-sensitivity (ethnic sensitivity) assessment and, where needed, bridging data should be anticipated.

Medical-device registration

Devices are tiered by risk into Class I (low), Class II (medium), and Class III (high). Class I devices are filed with the provincial NMPA office; Class II and III require NMPA or provincial registration (Class III and most Class II are registered with the NMPA/CMDE). Registration demands product technical requirements, type testing at an accredited lab, and a clinical evaluation or trial unless the device is exempt. Quality-system compliance (Good Manufacturing Practice for medical devices) is inspected, and overseas manufacturers of Class II/III devices must register their production site with the NMPA.

Another frequent blind spot in device registration is the choice of clinical-evaluation route. Not every Class II/III device requires a clinical trial: where a product is comparable to an already-marketed device of the same品种, a literature- and data-based “same-species” comparison can support exemption from trials; but novel or high-risk devices with no comparable predicate still need a trial. Companies should settle the clinical-evaluation strategy early — same-species comparison, trial exemption, or full trial — because it dictates the evidence-generation timeline and cost. In addition, the overseas manufacturing site of imported Class II/III devices must be registered with the NMPA, and the clean-room environment and quality system are subject to on-site inspection.

Post-market, labelling, and import considerations

Approved drugs and devices carry Chinese package inserts and labels; foreign-language-only labelling is not sufficient for the China market. Importers and responsible agents must maintain traceability and adverse-event reporting. Imported products enter through customs with the NMPA registration certificate as a key clearance document, and certain products face additional inspection by customs and SAMR. Reimbursement via the National Reimbursement Drug List and Volume-Based Procurement (VBP) are commercial-access factors a market-entry plan should weigh, though they sit outside the registration step itself.

A market-entry plan that stops at registration understates the real access barrier. The National Reimbursement Drug List (NRDL) negotiation and the Volume-Based Procurement (VBP, “集中带量采购”) program are the dominant commercial gateways: inclusion in the NRDL makes a drug reimbursable under basic medical insurance and unlocks hospital demand, while VBP tenders — which now cover many chemical generics, some biosimilars, and high-value devices — award volume in exchange for steep price cuts (often 50%–90%). Winning a VBP tender guarantees large, near-certain volume but at compressed margins, and losing can mean effective exclusion from public hospitals. Foreign companies should model the reimbursement and VBP scenario explicitly rather than treating them as downstream marketing concerns. Separately, data and market-exclusivity protections (e.g. for innovative drugs and paediatric/rare-disease indications) can shape the timing and defensibility of a launch.

Common pitfalls

  • Assuming foreign approval is enough. An FDA or EMA licence does not register a product in China. A separate NMPA pathway, meeting Chinese standards and often Chinese clinical data, is mandatory before any lawful marketing.
  • Relying on overseas trial data alone. Even where NMPA accepts foreign data under ICH-aligned guidance, trials are expected to follow Chinese GCP with local sites and Chinese patient populations; data without local relevance risks rejection or a requirement for bridging studies.
  • Treating the China responsible agent as a formality. The agent is the domestic MAH stand-in with real lifecycle duties — pharmacovigilance, recalls, traceability. A weak agent is a frequent root cause of enforcement.
  • Forgetting the registration certificate at customs. Import clearance hinges on the NMPA registration certificate as a key document; without it the product cannot enter, regardless of foreign readiness.
  • Planning only for registration, not reimbursement. For most drugs and many devices, NRDL inclusion and VBP outcome — not the registration grant — determine commercial viability in the China market.
  • Neglecting the device clinical-evaluation route analysis. Not all devices need trials, but the route choice (same-species comparison, exemption, or trial) sets the evidence cost and launch pace and should be settled at project kick-off.

What to do next

  • Identify the correct classification early (drug class, device Class I/II/III) because it dictates the entire evidence and review path.
  • Appoint a qualified China responsible agent to serve as the domestic party for imported-product registration and post-market duties.
  • Plan clinical trials to Chinese GCP with NMPA approval and local sites; do not assume overseas trial data alone will suffice.
  • Budget for type testing, stability studies, and GMP/site inspection lead times — these, not the fee, are usually the critical path.
  • Prepare Chinese labelling, inserts, and a pharmacovigilance/traceability system before launch.
  • Check reimbursement and VBP exposure as part of the commercial case, separate from registration.

Sources

  • National Medical Products Administration (NMPA) — official portal: https://www.nmpa.gov.cn
  • NMPA — English portal: https://english.nmpa.gov.cn
  • NMPA — government-service portal (drug/device registration and clinical-trial filing): https://zwfw.nmpa.gov.cn
  • NMPA — drug clinical-trial registration system (official portal, see service portal above): https://zwfw.nmpa.gov.cn
  • National Healthcare Security Administration (NHSA) — National Reimbursement Drug List & Volume-Based Procurement: https://www.nhsa.gov.cn/ (official portal)
  • State Administration for Market Regulation (SAMR) — medical-device and related oversight (official portal): https://www.samr.gov.cn/

Related reading

  • see also: Food & beverage market entry & licensing (48-fnb-market-entry-licensing)
  • see also: Financial services & fintech licensing (44-financial-services-fintech-licensing)
  • see also: Import-export licensing & customs clearance (50-import-export-customs-clearance)

医疗医药准入（药监局）

概述

药品与医疗器械是中国监管最严格的产品类别之一，主要由国家药品监督管理局（NMPA）监管。市场准入的关键在于注册，而非仅凭境外批准：在欧盟或美国合法销售的药品或器械，通常须走完中国自身的注册路径并符合中国标准后，方可在华上市。

本文说明药品与器械的注册路径、临床试验要求，以及外资药企与医疗器械公司应规划的实务步骤。本文仅为信息参考，不构成监管或法律意见；请以 NMPA 及合格的中国法律顾问确认最新要求。

药监局与上市许可持有人制度

NMPA（www.nmpa.gov.cn；英文：english.nmpa.gov.cn）统筹全国药品、医疗器械与化妆品监管，下设药品审评中心（CDE）、医疗器械技术审评中心（CMDE）及查验中心。中国实行上市许可持有人（MAH）制度：持有人——可以是境内主体，进口产品则为由境内责任代理人代表的境外生产企业——对产品全生命周期负责。因此，外国公司需要一家已登记的境内代理人，作为进口药品与器械的境内责任主体。

MAH 的职责并不止于取得批准，而是贯穿产品全生命周期——药物警戒与药品不良反应监测、上市后研究与风险管理计划、批签发与可追溯，以及召回执行。对进口产品而言，境内责任代理人就这些职责代行境外 MAH，并可能因中国市场质量与安全问题被 NMPA 直接追责。这使得代理人选择是一项治理决策，而非文书工作：代理人须具备监管能力、质量体系接口与人员，以履行不良反应及时报告与召回协调等义务。薄弱的代理人是上市后执法行动的反复根因。

药品注册路径

化学药品分为五类（1 类创新药，至 2–5 类的改良型、仿制及进口/境内同品种），生物制品遵循平行框架。创新药（1 类）须提供符合中国《药物临床试验质量管理规范》（GCP）与《药物非临床研究质量管理规范》（GLP）的完整非临床与临床数据。仿制药依赖生物等效性与质量和一致性研究。进口药品通过 NMPA 药品审评中心注册，申报资料以 CTD 式格式提交，多数新药须在完成 NMPA 批准的临床试验后，通过上市许可申请注册。

临床试验要求

在中国开展人体试验前，申办方须取得 NMPA 批准（或特定已列明试验须进行备案），并在国家药物临床试验登记与信息公示平台登记。试验须遵循中国 GCP；经资质的伦理委员会审查为强制要求，且通常期望纳入中国患者人群与研究中心，以保证数据对中国人群的相关姓。近年来，NMPA 已将多项技术指南与 ICH 标准接轨，以便利跨国多区域试验，但境外数据的本地相关性与 NMPA 接受度仍需审慎规划。

值得注意的另一点是沟通交流（Pre-IND 与沟通交流会议）机制的利用。NMPA 鼓励申办方在关键节点与 CDE 沟通，尤其是创新药在临床试验申请前、关键技术问题以及上市许可申请前。充分的沟通交流可显著降低后期被要求补充研究的风险。此外，对于在境外已上市、境内未上市的临床急需药品，附条件批准与优先审评审批通道可缩短上市时间，但须以承诺完成确证性试验为前提。境外数据用于中国注册时，还需注意种族敏感性（ethnic sensitivity）评估与必要的桥接数据。

医疗器械注册

器械按风险分为第一类（低）、第二类（中）、第三类（高）。第一类向省级药监部门备案；第二类与第三类须注册（第三类及多数第二类由 NMPA/CMDE 注册）。注册须提交产品技术要求、在资质实验室进行的型检，以及临床评价或临床试验（除非属于豁免目录）。质量体系合规（《医疗器械生产质量管理规范》）须接受检查，第二类/第三类境外生产企业须向 NMPA 登记其生产场地。

器械注册的另一常见盲点是临床评价路径的选择。并非所有二类、三类器械都需临床试验——若产品属同品种已上市器械且能通过同品种比对路径证明安全有效，可免于临床试验；但若无同品种可比或属高风险创新，仍须开展临床试验。企业应尽早做临床评价路径论证，确定是走同品种比对、免于临床，还是临床试验，因为该选择直接决定证据生成的时间与成本。此外，进口二类、三类器械的境外生产场地须完成 NMPA 登记，且洁净生产环境与质量体系须接受现场核查。

上市后、标签与进口考量

已获批药品与器械须配有中文说明书与标签；仅外文标签不足以进入中国市场。进口商与责任代理人须保持可追溯性与不良事件报告。进口产品清关时须以 NMPA 注册证作为关键单证，部分产品还须接受海关与市场监管总局的额外检验。通过《国家医保药品目录》与药品集中带量采购（VBP）获得的报销，是市场准入计划应权衡的商业准入因素，尽管其处于注册步骤之外。

止于注册的准入计划低估了真正的准入壁垒。《国家医保药品目录》（NRDL）谈判与药品集中带量采购（VBP，”带量采购”）是主导性的商业关口：纳入 NRDL 使药品可由基本医疗保险报销，撬动医院需求；而 VBP 带量采购——现覆盖众多化学仿制药、部分生物类似药与高值耗材——以大幅降价（常为 50%–90%）换取约定采购量。中标即锁定大且近乎确定的销量，但利润被压缩；落标则可能被公立医院体系实质排除。外国公司应显式建模报销与 VBP 情景，而非将其视为下游营销问题。此外，数据保护与市场独占期（如创新药及儿科/罕见病适应症的保护）会影响上市的时机与可防御性。

常见误读

  • 以为境外批准即足够。 FDA 或 EMA 许可并不等于在中国注册。在合法上市前，必须走完 NMPA 路径，符合中国标准并常需中国临床数据。
  • 仅凭境外试验数据。 即便 NMPA 在 ICH 接轨指引下接受境外数据，试验仍须遵循中国 GCP 并设国内研究中心、纳入中国患者人群；缺乏本地相关性的数据有被拒或要求桥接研究之险。
  • 把境内责任代理人当文书手续。 代理人是境内 MAH 代位人，承担真实的上市后职责——药物警戒、召回、可追溯。薄弱代理人是执法的常见根因。
  • 在海关忘了注册证。 进口清关以 NMPA 注册证为关键单证；缺少它，产品无法入境，与境外准备程度无关。
  • 只规划注册、不规划报销。 对多数药品与许多器械而言，NRDL 纳入与 VBP 结果——而非注册批件——决定其在中国市场的商业可行性。
  • 忽视临床评价路径论证。 并非所有器械都需临床试验，但路径选择（同品种比对、免于临床或临床试验）决定证据成本与上市节奏，应在立项时即论证。

下一步建议

  • 尽早确定正确分类（药品类别、器械一/二/三类），因其决定整个证据与审评路径。
  • 指定合格的境内责任代理人，作为进口产品注册与上市后职责的境内主体。
  • 按中国 GCP 规划临床试验并取得 NMPA 批准、设立国内研究中心；勿假设仅凭境外试验数据即可。
  • 为型检、稳定性研究及 GMP/场地核查留出时间——通常关键路径在于此而非费用。
  • 上市前准备好中文标签、说明书，以及药物警戒/可追溯体系。
  • 将报销与带量采购敞口作为商业论证的一部分另行评估，与注册分离。

来源

  • 国家药品监督管理局（NMPA）——官方门户：https://www.nmpa.gov.cn
  • NMPA——英文门户：https://english.nmpa.gov.cn
  • NMPA——政务服务门户（药品/器械注册与临床试验登记）：https://zwfw.nmpa.gov.cn
  • NMPA——药物临床试验登记与信息公示平台（见政务服务门户）：https://zwfw.nmpa.gov.cn
  • 国家医疗保障局（NHSA）——国家医保药品目录与集中带量采购：https://www.nhsa.gov.cn/（官方门户）
  • 国家市场监督管理总局（SAMR）——医疗器械及相关监管（官方门户）：https://www.samr.gov.cn/

相关阅读

  • 参见：餐饮食品入华与许可（48-fnb-market-entry-licensing）
  • 参见：金融服务与金融科技牌照（44-financial-services-fintech-licensing）
  • 参见：进出口许可与海关清关（50-import-export-customs-clearances）